

ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2014

Cancer in Slovenia



Rak
v Sloveniji

2014

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2014 / Cancer in Slovenia 2014

Uredniški odbor / Editorial Board

Vesna Zadnik, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Urška Ivanuš,
Katja Jarm, Vera Pompe-Kirn, Maja Primic Žakelj,
Primož Strojani, Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Tina Žagar in Katarina Lokar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo, Ljubljana

Tisk / Printing

Grafika Gracer d. o. o., Celje

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2014. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2017.

Cancer in Slovenia 2014. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2017.

Osebe Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Maruška Ferjančič, Andrej Kirn, Andrej Krašovec, Katarina Lokar,
Darja Strle, Fani Škrlec, Polona Škulj, Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:

<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

<http://www.slora.si/>
<http://www.slora.si/en/>

Uvod	7
Viri podatkov in metode registracije	9
Viri podatkov	9
Priprava podatkov za računalniško obdelavo	10
Kakovost podatkov RRRS in popolnost registracije	11
Statistične metode	12
Incidenca in umrljivost	12
Grobe in starostno specifične stopnje	12
Starostno standardizirane stopnje	12
Kumulativne stopnje in kumulativno tveganje	13
Prevalenca	13
Preživetje	14
Zemljevidi	14
Prebivalstvo Slovenije	15
Rak v Sloveniji 2014	16
Zahvala	20
Introduction	21
Data sources and methods of registration	23
Data sources	23
Preparation of data for computer processing	24
Data quality and completeness of registration	25
Statistical methods	27
Incidence and mortality	27
Crude and age specific rates	27
Age standardised rates	27
Cumulative incidence rate and cumulative risk	28
Prevalence	28
Survival	28
Maps	29
Population of Slovenia	30
Cancer in Slovenia 2014	31
Acknowledgment	35
Reference / References	36

Slike / Figures

Slika 1:	Breme raka, Slovenija 2014.	38
Figure 1:	Cancer burden, Slovenia 2014.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2014.	38
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2014.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2014.	39
Figure 3:	The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2014.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2014.	40
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2014.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2014.	41
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2014.	
Slika 6:	Petletno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2005–2009 in 2010–2014 po spolu in pri obeh spolih skupaj.	42
Figure 6:	Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2005–2009 and 2010–2014 by sex and for both sexes together.	
Slika 7a:	Zemljevid raka pri moških po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	45
Figure 7a:	Map of male cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7b:	Zemljevid raka pri ženskah po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	45
Figure 7b:	Map of female cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7c:	Zemljevid raka debelega črevesa in danke po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	46
Figure 7c:	Map of colorectal cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7d:	Zemljevid želodčnega raka po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	46
Figure 7d:	Map of stomach cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7e:	Zemljevid pljučnega raka po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	47
Figure 7e:	Map of lung cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7f:	Zemljevid rakov glave in vratu po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	47
Figure 7f:	Map of head and neck cancers by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7g:	Zemljevid raka prostate po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	48
Figure 7g:	Map of prostate cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	

Slika 7h:	Zemljevid kožnega melanoma po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	48
Figure 7h:	Map of skin melanoma by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7i:	Zemljevid raka dojke pri ženskah po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	49
Figure 7i:	Map of female breast cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	
Slika 7j:	Zemljevid raka materničnega vratu po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.	49
Figure 7j:	Map of cervical cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2005–2014 in 2017.	50
Table 1:	Observed and estimated cancer incidence, Slovenia 2005–2014 and 2017.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2014.	51
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2014.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2014.	52
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2014.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2014.	56
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2014.	
Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2014.	60
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2014.	
Tabela 6a:	Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2014.	66
Table 6a:	Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2014.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2014.	67
Table 6b:	Age standardised incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2014.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2014.	68
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2014.	
Tabela 8:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2014.	77
Table 8:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2014.	
Tabela 9:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2014.	80
Table 9:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2014.	

Tabela 10:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2014.	81
Table 10:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2014.	
Tabela 11a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.	83
Table 11a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 11b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	84
Table 11b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by surgery during their first treatment by primary site and treatment institution.	
Tabela 11c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po lokacijah raka in bolnici posega.	85
Table 11c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by systemic therapy during their first treatment by primary site and treatment institution.	
Tabela 12:	Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2014.	86
Table 12:	Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2014.	
Tabela 13:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2014.	87
Table 13:	Cancer mortality by site, by sex and by age, Slovenia 2014.	
Tabela 14:	Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2010–2014 po spolu.	90
Table 14:	One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2010–2014 by sex.	
Izbor publikacij / Selected publications		91

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2017); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977 in 2007–2014), v vmesnem obdobju (1978–2006) pod imenom *Incidenca raka v Sloveniji*, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na*

petih kontinentih (Cancer Incidence in Five Continents), ki jo izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah ECO, GLOBOCAN in ACCIS. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah EUROCARE-2, EUROCARE-3, EUROCARE-4, EUROCARE-5, EUROCARE-6, CONCORD-1, CONCORD-2, CONCORD-3, RARECARE in EUNICE.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbira RRRS do zaključenega leta obdelave, trenutno 2014 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.


Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00 in št. 47/15). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dopolnilni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojke in SVIT za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. S prijavnici zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Veliko časa porabimo za poizvedbe o bolnikih, za katere na prijavnicih niso zapisani popolni ali ustrezni podatki ter za tiste o katerih dobimo prvo informacijo šele iz enega od dopolnilnih virov.

Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Podrobne analize prostorske razporeditve raka nam omogoča točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS. V Tabeli 6 tako prikazujemo breme raka na ravni 12 statističnih regij, kot jih predvideva Uredba o standardni klasifikaciji teritorialnih enot – SKTE (2007) in kot so bile v veljavi leta 2014.

Slovenske statistične regije



V prilogi letošnjega poročila na zemljevidih prikazujemo incidenco najpomembnejših rakov tudi po najmanjših možnih prostorskih enotah za rutinsko prikazovanje – kot osnovno enoto smo v tem prikazu uporabili državnozborska volišča, kot jih definira RPE, pri čemer smo jih nekaj med seboj združili zaradi zahtev po varovanju osebnih podatkov. Zemljevidi so tako sestavljeni iz 3.104 geografskih enot (volišč) v katerih je leta 2011 bivalo med 30 in 4500 prebivalcev.

Priprava podatkov za računalniško obdelavo

Podatke, prispere v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961-1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Ginekološke tumorje tako opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu pa beležimo tudi velikost po Clarku in Breslowu. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno..

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2017 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo program Joinpoint Regression Program (Version 4.1.1 – August 2014), ki je narejen na podlagi metodologije, ki so jo razvili Kim s sodelavci.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so v istem obdobju izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* (incidenčna oz. umrljivostna stopnja) se izračuna na enak način, vendar za posamezno starostno skupino.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, ki bi jo opazili, če bi bila starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji prikazujemo še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002.

Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,7/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 7,4-odstotno. To pomeni, da bo 7,4 % deklic (ali približno ena od 13), rojenih leta 2014, do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih diagnoz.

Preživetje

Pri skupinah bolnikov preživetje predstavlja delež bolnikov, ki so po izbranem časovnem obdobju od postavitve diagnoze še živi. Možnosti in metod za izračun preživetja je več. Osnovna in hkrati najpreprostejša mera preživetja je tako imenovano opazovano preživetje, kjer v izračun vključimo vse smrti, tudi tiste, ki jih ni povzročilo rakavo obolenje. Za oceno preživetij bolnikov z rakom, v kateri upoštevamo kot vzrok smrti le proučevanega raka, v populacijskih izračunih uporabljamo metode relativnega in čistega preživetja. Uradni vzroki smrti namreč niso dovolj točni, da bi bil izračun vzročno specifičnega opazovanega preživetja na populacijski ravni dovolj zanesljiv.

Relativno in čisto preživetje se izračunata s statističnim primerjanjem opazovanega preživetja proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki (t.i. pričakovano preživetje). Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. V letošnjem poročilu prvič prikazujemo čisto preživetje izračunano po metodi Pohar-Perme, do sedaj smo prikazovali preživetje izračunano po metodi Ederer-II, ki je ena od metod relativnega preživetja.

Opozarjamo še, da metoda čistega preživetja, uporabljena za izračun preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati preživetje na spletnem portalu SLORA. Na spletnem portalu SLORA prikazujemo opazovano preživetje in pa relativno preživetje izračunano po Hakulinenovi metodi.

Zemljevidi

Zemljevidi incidence raka (*Slika 7a-7j*) so pripravljene na najmanjših možnih prostorskih enotah za rutinsko prikazovanje – 3104 prilagojenih državnozborskih voliščih. Za vsako enoto prikazujemo prostorsko glajene standardizirane količnike incidence (SKI). V prvem koraku smo z metodo *posredne standardizacije* izračunali dejanski SKI za vsako enoto. SKI je razmerje med opazovanim in pričakovanim številom raka v primeru, da bi bile starostno specifične incidenčne stopnje v posameznih enotah take, kot so bile povprečne starostno specifične stopnje v Sloveniji v vsem opazovanem obdobju (2005–2014). SKI je približek relativnemu tveganju raka v posamezni enoti v opazovanem časovnem obdobju. Kadar je SKI enak ena to interpretiramo, da imajo prebivalci te prostorske enote enako tveganje kot je bila v Sloveniji v istem časovnem obdobju. Ker je število primerov v posamezni enoti majhno oziroma v nekaterih enotah zbolelih z rakom sploh ni bilo ter je zaradi majhnega števila prebivalcev dejansko število zbolelih v posamezni enoti močno podvrženo naključju in zato za prikaz neprimerno, prikazujemo na zemljevidih prostorsko glajene vrednosti SKI. Za glajenje smo uporabili vrednosti v sosednjih enotah ter v celotni Sloveniji. Prostorsko glajenje je bilo izvedeno s pomočjo Besag-York-Mollié-ovega Bayesovega modela v programu WinBUGS. Za grafični prikaz smo izračunane prostorsko glajene SKI razdelili v 7 enako velikih razredov. Volišča z majhnim tveganjem so obarvana v odtenkih modre, tista s povprečnim tveganjem (vrednosti okoli ena) rumeno, tista z večjim tveganjem pa v odtenkih rdeče.

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila struktura v letih med dvema popisnima letoma enaka kot v najbližjem popisnem letu. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2014 so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	109.837	56.577	53.260
5–9	101.378	52.022	49.356
10–14	91.305	47.058	44.247
15–19	95.674	49.303	46.371
20–24	109.701	56.278	53.423
25–29	134.654	70.046	64.608
30–34	151.093	79.253	71.840
35–39	156.329	81.903	74.426
40–44	146.919	76.507	70.412
45–49	154.290	78.559	75.731
50–54	153.041	77.738	75.303
55–59	151.739	76.755	74.984
60–64	141.203	70.781	70.422
65–69	100.608	47.830	52.778
70–74	91.944	40.959	50.985
75–79	74.014	30.141	43.873
80+	97.894	29.709	68.185
Skupaj	2.061.623	1.021.419	1.040.204

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2014.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	117.005	57.421	59.584
Podravska	323.034	160.248	162.786
Koroška	71.390	35.854	35.536
Savinjska	259.935	130.030	129.905
Zasavska	42.824	20.961	21.863
Spodnjeposavska	70.599	35.578	35.021
JV Slovenija	141.632	71.371	70.261
Osrednjeslovenska	547.730	267.408	280.322
Gorenjska	203.894	100.933	102.961
Notranjsko-Kraška	52.517	26.500	26.017
Goriška	118.335	59.154	59.181
Obalno-Kraška	112.728	55.961	56.767
Slovenija	2.061.623	1.021.419	1.040.204

Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2014.

Leta 2014 je v Sloveniji za rakom zbolelo 13.753 ljudi, 7.459 moških in 6.294 žensk. (Slika 1), umrlo pa 5.898 ljudi, 3.310 moških in 2.588 žensk. Od rojenih leta 2014 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (Tabela 5).

Konec decembra 2014 je živel 98.331 ljudi (43.905 moških in 54.426 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (Slika 1). Ocenjujemo, da je leta 2017 za rakom zbolelo približno 15.000 prebivalcev Slovenije, približno 8.400 moških in 6.600 žensk. Ocene incidence za posamezne lokacije raka so prikazane v Tabeli 1 skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Ogroženost z rakom se zmerno večja in je največja v starejših letih; od vseh bolnikov z rakom je leta 2014 kar 61 % moških in 60 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (Slika 2). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še naprej večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v Tabeli 2 poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo za namene različnih primerjav uporabili tri standardne populacije svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), rak prostate, debelega črevesa in danke, dojke in pljuč – obsega 57 % vseh novih primerov rakavih bolezni (Slika 3). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 19 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu rak dojk, ki je predstavljal petino primerov vseh rakov pri ženskah (Slika 3).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 700 % pri moških in za 500 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 2,6 % letno, pri ženskah pa za 1,6 %. Groba umrljivostna stopnja se je pri obeh spolih v zadnjih 10-ih letih večala povprečno za 1,2 % letno (Slika 4). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri obeh spolih večala v povprečju le za 0,6 % letno. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (Slika 4), v zadnjih 10-ih letih pri moških za 2,1 % letno, pri ženskah pa za 1,2 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, z izjemo kumulativne incidence, so statistično značilne pri stopnji tveganja 0,05.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 85/100.000, v zadnjih desetih letih se postopno manjša (za 0,8 % povprečno letno), strmo pa pljučnega raka prehitevata rak prostate

(povečanje za 4,8 % povprečno letno) in kožni nemelanomski rak (povečanje za 5,0 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno že dosegli. Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (SVIT). Incidenca raka debelega črevesa in danke se je pri moških med leti 2005 in 2010 povečevala za 7,3 % letno, od leta 2010 do 2014 pa pada za 5,2 % letno. Pri ženskah se večajo incidenčne stopnje raka dojk (za 1,4 % povprečno letno), kože, razen melanoma (za 4,0 % povprečno letno), pljučnega raka (za 4,0 % povprečno letno) in materničnega telesa (za 1,3 % povprečno letno). Incidenčna stopnja raka materničnega vratu se od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo manjša (za 4,4 % povprečno letno v zadnjih desetih letih). Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa SVIT spreminja časovni trend pojavljanja raka debelega črevesa in danke – med leti 2005 in 2010 se je incidenca povečevala za 4,5 % letno, od leta 2010 do 2014 pa pada za 5,9 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2010-2014 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2005-2009). Pri moških se je skupno preživetje povečalo za 6 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje za skoraj 4 odstotnih točk. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Preživetje bolnic, zbolelih v obeh petletnih obdobjih, se ni bistveno spreminjalo in znaša 59 %.

Posebno pozornost v letošnjem poročilu posvečamo geografskemu razporejanju najpogostejših rakov. V tematski prilogi na *Slikah 7a-7j* tako objavljamo **zemljevide prostorsko glajenih standardiziranih količnikov incidenc** posameznih vrst rakov za zadnje 10-letno obdobje 2005-2014 pripravljenih na nivoju državnozborskih volišč. Kljub uporabi vseh ustreznih tehnik za izračun in prikaz pa so uporabljene enote še vedno premajhne, da bi bilo možno na podlagi vrednosti za posamezno enoto sklepati o dejanskem bremenu raka v tem volišču. Pripravljeni zemljevidi so namenjeni prikazu splošnega prostorskega razporejanja raka v državi ter morebitnemu razkritju večjih področij, kjer je posamezna vrsta raka v presežku. Pri vseh rakah skupaj prikazanih na *Slikah 7a* in *7b*, pri rakah debelega črevesa in danke (*Slika 7c*) in raku dojke (*Slika 7i*) tako na zemljevidu ni področji, ki bi od povprečja odstopale za več kot 30 %. Se pa pri raku dojke nakazuje večje tveganje v okolici Ljubljane in Maribora ter na Gorenjskem in Primorskem. Najverjetneje gre večjo ogroženost pripisati boljšemu socialno-ekonomskemu položaju žensk v teh okoljih, saj med pomembnejše znane dejavnike tveganja raka dojk sodijo tudi kasnejši prvi porod, manjše število otrok ter ničrodnost. Želodčni rak (*Slika 7d*) se pogosteje

pojavlja v severovzhodni Sloveniji. Povezujemo ga z okužbo z bakterijo *Helicobacter pylori*, predvsem v zgodnjem otroštvu, z nezadostnim vnosom sadja in zelenjave, prevelikim vnosom soli, uživanjem prekajenih mesnin ter kajenjem. Pljučnega raka (*Slika 7e*), ki ga v prvi vrsti povezujemo s kajenjem, tega pa dandanes čedalje pogosteje s slabšim socio-ekonomskim statusom, je največ na Kočevskem, v Zasavju ter na Koroškem. Tveganje kožnega melanoma (*Slika 7h*), ki ga povezujemo z visokimi intermitentnimi izpostavljenostmi naravnim in umetnim UV žarkom, je največ v osrednji Sloveniji in na Primorskem. Rakov glave in vratu (*Slika 7f*), tipično pivsko-kadilskih rakov, je značilno več v celotni vzhodni Sloveniji. Podobna prostorska razporeditev z večjim tveganjem na vzhodu države je opazna tudi pri raku materničnega vratu (*Slika 7j*), vendar pa gre v tem primeru najverjetneje za vplive izvajanja presejalnega programa (znana je manjša udeležba v presejalnem programu ZORA na vzhodu) in ne toliko za večjo izpostavljenost dejavnikom tveganja. Povečano breme raka prostate (*Slikah 7g*) v Pomurju ter deloma na Dolenjskem in v okolici Ljubljane je s sedanjim epidemiološkim znanjem težko razložiti. Dejavniki tveganja raka prostate so zaenkrat slabo raziskani. Vemo pa, da na incidenco raka prostate v veliki meri vpliva predvsem pogostost rabe testa PSA – kakšne so razlike v testiranju za PSA po slovenskih pokrajinah ni znano.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2014 pri 94,2 % od 13.753 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,6 % pa z drugimi preiskavami. Spodbudno je, da je že več let le 0,2 % primerov v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti; RRRS verjetno niso bili prijavljeni ker niso bili zdravljeni v bolnišnici zaradi starosti ali napredovale bolezni. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v številu in starostni strukturi prebivalcev. *Tabeli 6a* in *6b* smo v letošnjem poročilu razširili z nekaj dodatnimi lokacijami.

Kakšna je bila morfološka slika malignomov pri 12.953 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ekстранodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekстранodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi.

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov; Objavljamo le podatke o prvem kurativnem zdravljenju. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2014. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 13* so uradni podatki o umrljivosti za rakom v letu 2014; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora.

V letošnje poročilo dodajamo prvič tudi *Tabelo 14* v kateri so prikazana 1-, 3- in 5- letna čista preživetja bolnikov zbolelih med leti 2009 in 2014.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Odgovore na vsa strokovna vprašanja nam priskrbijo zdravniki specialisti z Onkološkega inštituta Ljubljana. V prav posebno pomoč pa so vsi strokovni nasveti s področja patologije, ki nam jih že vrsto let nudi doc. dr. Matej Bračko, dr. med., specialist patolog.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the CRRS, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnostics, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the CRRS are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2017) are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, entitled *Cancer in Slovenia* in years 1965–1977 and 2007–2014, and *Cancer Incidence in Slovenia* in the period 1978–2006. Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the *Cancer Incidence in Five Continents* issued by the International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *CONCORD-3*, *RARECARE* and *EUNICE*.

In 2010, the CRRS's database has been upgraded and data processing modernized. At the same time an *interactive web portal* named SLORA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAK/cancer". It is available at www.slora.si/en/. It enables a simple access to data on cancer in Slovenia collected by the CRRS (incidence, prevalence and survival; currently till 2014) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) as well as the comparisons with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00 and 47/15). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment. Complementary sources of information are death certificates that we get from National Institute of Public Health of Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of pre-cancerous and early cancerous lesions of cervix uteri, DORA for early detection of breast cancer and SVIT for the detection of pre-cancerous lesions and cancer of colon and rectum. The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Where patients' data reported on notifications are not complete or adequate and where the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the CRRS's staff.

Calculation of patient prevalence and survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the percentage of the lost to follow-up in CRRS is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

Detailed analyses of the spatial distribution of cancer are enabled by accurately defined addresses of patients with cancer and regular connection to the Registry of Spatial Units of the Surveying and Mapping Authority. Table 6 shows cancer burden at the level of 12 statistical regions in accordance with the Decree on the Standard Classification of Territorial Units - SKTE (2007) and as in effect in 2014.

In the attachment to this year's report, the incidence of the most important cancers is shown on the maps at the level of the smallest possible spatial units for routine display. The parliament polling stations (as defined by the Registry of Spatial Units) were used as the base unit; some of them were joined together due to the requirements for the protection of personal data. Therefore, the maps were composed of 3,104 geographical units (polling stations) in which between 30 to 4500 inhabitants lived in the year 2011.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal CRRS guidelines.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8).

When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two being assigned to C96.7 and the polycythaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification

of Diseases for Oncology (third revision, 2011 update) follows this classification. Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used for solid tumors, classifying them into localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Stage according to TNM or any other appropriate classification is also stored in the CRRS database, if available. Gynecological tumors are thus defined also according to the FIGO classification and in skin melanoma size according to Clark's level and Breslow's thickness is registered. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of

patients in order to provide us with information about their vital status and among them we often find cases that have not been entered into the CRRS database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2017 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et al.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 inhabitants, while *crude mortality rate* is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) in the same period; it is expressed per 100,000 person-years. The age specific rate (incidence or mortality rate) is calculated in the same way, but for each age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (CR), (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 inhabitants. The cumulative rate can be interpreted as a form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed as a percentage. If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CRisk = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 7.7/100 can be used to estimate cumulative risk of breast cancer that is in this case 7.4%. This means that 7.4% of women born in 2017 (approximately one out of 13) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diagnoses.

Survival

In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. There are several options and methods for survival calculation. The basic and at the same time the simplest measure of survival is the so-called observed survival, where all deaths, also those

not caused by cancer, are included in the calculation. In order to evaluate the survival of cancer patients, which takes into account the cancer-specific deaths only, the methods of relative and net survival are used in population studies. The data on official causes of death are often insufficiently accurate for the calculation of the causal specific observed survival at the population level.

Relative and net survival are calculated by statistical comparison of the observed survival in the group of patients under study and survival with respect to gender and age over a certain period of time in the population the patients come from (i.e. the expected survival). The expected survival is calculated from general mortality data and is published routinely in the form of country specific mortality tables within the framework of its vital statistics; for our calculations, the Slovenian complete yearly life tables are used. In this year's report, we present for the first time the net survival calculated using the Pohar-Perme method; until now we calculated survival with the Ederer-II approach, which is one of the methods of relative survival.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA. The SLORA web portal shows the observed survival and the relative survival computed by the Hakulinen method.

Maps

Cancer incidence maps (*Figure 7a - 7j*) are prepared for the smallest possible spatial units for routine display – 3,104 adjusted polling stations for parliament elections. Spatially smoothed standardized incidence ratios (SIR) are displayed for each unit. In the first step, the actual SIR for each unit was calculated using the *indirect method of standardization*. A SIR is the ratio of the observed number of cancer cases to the expected number of cancer cases when age specific incidence rates in individual spatial units might be such as the average age specific incidence rates in Slovenia for the whole observed period (2005-2014). A SIR can be interpreted as an estimate of the relative risk of cancer in individual unit in the given time period. A SIR equal to one indicates that the inhabitants of this spatial unit have the same risk to the one in Slovenia in the same time period. Due to the small or zero number of cancer cases in individual unit, and due to the small number of inhabitants, the actual number of cancer patients in the individual unit is strongly influenced by chance, hence, not suitable for display. Therefore we created smoothed maps of SIR values. For smoothing we used values from neighbouring units and from the whole of Slovenia. The applied smoothing method was based on the Bayesian Besag-York-Mollié model and computed in the WinBUGS program. For the graphic representation, the calculated spatially smoothed SIR values were divided in 7 equal class intervals. Polling stations with low risk are coloured in shades of blue, those with an average risk (values around 1) yellow, and those with a higher risk are coloured in shades of red.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure in the between two censuses years was the same to the nearest census. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports the population data on July 1 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2014 by age and by sex are presented.

Age	Total	Males	Females
0–4	109,837	56,577	53,260
5–9	101,378	52,022	49,356
10–14	91,305	47,058	44,247
15–19	95,674	49,303	46,371
20–24	109,701	56,278	53,423
25–29	134,654	70,046	64,608
30–34	151,093	79,253	71,840
35–39	156,329	81,903	74,426
40–44	146,919	76,507	70,412
45–49	154,290	78,559	75,731
50–54	153,041	77,738	75,303
55–59	151,739	76,755	74,984
60–64	141,203	70,781	70,422
65–69	100,608	47,830	52,778
70–74	91,944	40,959	50,985
75–79	74,014	30,141	43,873
80+	97,894	29,709	68,185
Total	2,061,623	1,021,419	1,040,204

Population of Slovenia by age and by sex, July 1, 2014.

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard “statistical” definition.

Statistical region	Total	Males	Females
Pomurska	117,005	57,421	59,584
Podravska	323,034	160,248	162,786
Koroška	71,390	35,854	35,536
Savinjska	259,935	130,030	129,905
Zasavska	42,824	20,961	21,863
Spodnjeposavska	70,599	35,578	35,021
JV Slovenija	141,632	71,371	70,261
Osrednjeslovenska	547,730	267,408	280,322
Gorenjska	203,894	100,933	102,961
Notranjsko-Kraška	52,517	26,500	26,017
Goriška	118,335	59,154	59,181
Obalno-Kraška	112,728	55,961	56,767
Slovenia	2,061,623	1,021,419	1,040,204

Population by Slovenian statistical regions and by sex, July 1, 2014.

In 2014, 13,753 patients were diagnosed with cancer, 7,459 males and 6,294 females, and 5,898 patients died from cancer, 3,310 males and 2,588 females (*Figure 1*). From those born in 2014, one in two males and one in three females are expected to develop cancer by their age of 74 (*Table 5*).

At the end of December 2014, there were 98,331 people (43,905 males and 54,426 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated that in 2017 there was about 15,000 Slovenian inhabitants newly diagnosed with cancer, approximately 8,400 males and 6,600 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2014, 61% males and 60% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will continue to increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For the purposes of different comparisons with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (skin – except melanoma, prostate, colorectal, lung and breast) comprise 57% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2014 was prostate (19.0% of all new cases). In females, breast cancer was the most frequent cancer site with one fifth of all new cases (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 700% in males and by 500% in females. In the last 10 years, the average annual increase in males was 2.6% and 1.6% in females. The increase in crude mortality rate in the last 10 years was on average 1.2% per year in both sexes (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in both sexes was 0.6%. Cumulative mortality rate is decreasing since 1985 in both sexes, in the last 10 years, in males on average by 2.1% and in females on average by 1.2% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer. All average annual changes with the exception of cumulative incidence are statistically significant at a risk level of 0.05.

The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing (by 0.8% per year on average) and was finally overcome by prostate cancer (average increase by 4.8% per year) and by non-melanoma skin cancer (average increase by 5.0% per year). The huge increase in

prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. The data for the last few years show that the incidence peak of prostate cancer has been reached. Similarly, the changes in the colorectal cancer incidence should be interpreted taking into consideration the changes in the diagnostic practice – in Slovenia the National colorectal cancer screening programme (SVIT) has been introduced in 2009. The average annual increase in colorectal cancers in males in the period 2005–2010 was 7.3%, but there was an average annual decrease of 5.2% in the following years 2010–2014. In females, the incidence rate of breast (by 1.4% per year on average), lung (by 4.0% per year on average), non-melanoma skin (by 4.0% per year on average), and uterine cancer (by 1.3% per year on average) is increasing, while the incidence of cervical cancer is rapidly decreasing since the introduction of the National cervical cancer screening programme (ZORA); the average annual decrease in last ten years was 4.4%. Like in males also in females the colorectal cancer incidence time trends has been changed because the national screening programme SVIT has been introduced: in the period 2005–2010 the incidence raised for 4.5% annually, but in the years 2010–2014 it decreased by 5.9% annually. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2010–2014 is presented and compared to those diagnosed in 2005–2009. In males, the overall five-year relative survival increased for 6 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased for 4 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall survival in both time periods has not changed much and amounts to 59%.

In this year's report a special attention is given to the geographic distribution of the most common cancers. In the thematic supplement in *Figures 7a - 7j* **maps of spatially smoothed standardized incidence ratios** of individual types of cancer for the last 10-year period (2005 – 2014) prepared at the level of polling stations for parliament elections are presented. Despite the use of all the appropriate calculation and display techniques, the applied units are still too small to effectively describe the actual cancer burden for chosen polling station. Our maps are meant to show the general spatial distribution of cancer in the country and to disclose the regions where the individual type of cancer could be in excess. In all cancers together, displayed in *Figures 7a* and *7b*, in colon and rectal cancer (*Figure 7c*), and breast cancer (*Figure 7i*), there are no areas on the map that deviate from the average by more than 30%. However, in breast cancer, there is an indication of higher risk in the vicinity of Ljubljana and Maribor, and in the Gorenjska and Primorska regions. Most likely the greater risk can be attributed to the better socioeconomic status of women in these environments, as more relevant risk factors associated with breast cancer are later age at first delivery, a smaller number

of children, and nulliparity. Stomach cancer (*Figure 7d*) is more commonly found in north-eastern Slovenia. It is associated with *Helicobacter pylori* infection, especially in early childhood, with insufficient intake of fruit and vegetables, excessive salt intake, consumption of smoked meat products, and smoking. Lung cancer (*Figure 7e*) that is primarily associated with smoking, which is nowadays more commonly related to lower socioeconomic status, is the highest in Kočevje, Zasavje and in Koroška region. The risk of skin melanoma (*Figure 7h*), which is associated with high intermittent exposure to natural and artificial UV radiation, is highest in Central Slovenia and in the Primorska region. Head and neck cancers (*Figure 7f*), typically linked to alcohol and tobacco consumption, are consistently more common in the entire eastern part of Slovenia. A similar spatial distribution with a higher risk in the east of the country is also visible in cervical cancer (*Figure 7j*), but in this case, it is most likely due to the impact of the screening program (a known smaller participation in the screening program ZORA in the east), and not so much due to greater exposure to risk factors. The increased burden of prostate cancer (*Figure 7g*) in Pomurje and partly in Dolenjska and around Ljubljana is difficult to explain with the current epidemiological knowledge. The risk factors for prostate cancer are poorly researched. However, we know that the incidence of prostate cancer is largely influenced by frequent use of the PSA test - the difference in testing for PSA across Slovenian regions is not known.

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2014, in 94.2% from 13,753 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 5.6% with other investigations. It is encouraging that for several years only 0.2% of cases in the CRRS were registered from death certificates only. They were probably not reported to CRRS because they represent the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different number and age structure of population in these regions. *Tables 6a* and *6b* were expanded in this year's report with some additional locations.

The morphology of tumours in 12,953 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extra nodal sites, only the absolute numbers are given.

Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization.

Table 11 presents basic data on cancer patients' primary curative treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b and 11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 12*, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2014 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years).

In *Table 13*, there are official data on cancer mortality in 2014. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (<http://www.slora.si/en/>).

Table 14 is added to this year's report for the first time. It shows 1-, 3-, 5-, and 10-years net survival of patients diagnosed between 2009 and 2014.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other healthcare institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought and completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Maruška Ferjančič and Mrs. Polona Škulj from the Ljubljana Institute of Oncology Hospital Registry.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

Answers to all expert questions are provided by clinical specialists from the Institute of Oncology Ljubljana. Expert advice in the field of pathology is especially helpful, and has been offered to us for many years by pathology specialist, assist. prof. dr. Matej Bračko, MD.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: <http://ci5.iarc.fr>.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCORE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCORE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; 15: 23–34
- Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999–2007: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2014;15: 35-47.
- Coleman, MP, Quaresma, M, Berrino, F., and the CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*. 2008; 9: 730–756
- Allemani C, Weir HK, Carreira H ... and the CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015; 385: 977-1010.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47; 2493–511.

- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- World Health Organisation. International classification of diseases for Oncology. 3rd Edition. Geneva: World Health Organisation, 2000.
- World Health Organisation. International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013.
- Swerdlow SH., Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2. Geneva: World Health Organization, 2008.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. *Stat Med* 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: <http://pxweb.stat.si/>.
- Dyba T, Hakulinen T, Päiväranta L. A simple non-linear model in incidence prediction. *Statistics in Medicine* 16: 2297–309, 1997.
- Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Statistics in medicine* 2000; 19(3): 335–51.
- Pohar M, Stare J. Relative survival analysis in R. *Computer Methods and Programs in Biomedicine* 2006; 81: 272–8.
- Perme MP, Stare J, Estève J. On estimation in relative survival. *Biometrics*. 2012;68(1):113-20.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.


Slika 1: Breme raka, Slovenija 2014.

Figure 1: Cancer burden, Slovenia 2014.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2014.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2014.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2014.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2014.



MOŠKI IN ŽENSKÉ / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danko / Colorectum (C18–C20)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2014.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2014.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2014.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2014.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level


Slika 6: Petletno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2005–2009 in 2010–2014 po spolu in pri obeh spolih skupaj.

Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2005–2009 and 2010–2014 by sex and for both sexes together.




Slika 6: Nadaljevanje.
Figure 6: Continued.

ŽENSKE / FEMALES




Slika 6: Nadaljevanje.
Figure 6: Continued.




Slika 7a: Zemljevid raka pri moških po voličih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7a: Map of male cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7b: Zemljevid raka pri ženskah po voličih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7b: Map of female cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7c: Zemljevid raka debelega črevesa in danke po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7c: Map of colorectal cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7d: Zemljevid želodčnega raka po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7d: Map of stomach cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7e: Zemljevid pljučnega raka po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7e: Map of lung cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7f: Zemljevid rakov glave in vratu po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7f: Map of head and neck cancers by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7g: Zemljevid raka prostate po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7g: Map of prostate cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Slika 7h: Zemljevid kožnega melanoma po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7h: Map of skin melanoma by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.



Slika 7i: Zemljevid raka dojke pri ženskah po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7i: Map of female breast cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.



Slika 7j: Zemljevid raka materničnega vratu po voliščih; prostorsko glajeni standardizirani količniki incidence, Slovenija 2005–2014.

Figure 7j: Map of cervical cancer by voting units; spatially smoothed standardised incidence ratios, Slovenia 2005–2014.




Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2005–2014 in 2017.

Table 1: Observed and estimated cancer incidence, Slovenia 2005–2014 and 2017.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2005–2009		Povprečne letne opazovane vrednosti 2010–2014		Ocena za 2017			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
			Average annual observed values 2005–2009		Average annual observed values 2010–2014		Estimation for 2017			
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
C00–C96	Vse lokacije All sites	M+Ž	11925	590,7	13561	659,7	14981	14637–15325	725	709–742
		M	6315	635,3	7386	725,8	8355	8086–8623	815	789–841
		Ž	5610	547,4	6175	594,9	6626	6411–6842	637	616–657
C00–C14	Usta in žrelo Mouth and pharynx	M	264	26,6	274	26,9	285	240–331	28	23–32
		Ž	68	6,6	72	7,0	73	50–97	7	5–9
C15	Požiralnik Oesophagus	M	71	7,2	75	7,3	80	56–104	8	5–10
		Ž	16	1,6	15	1,5	12	3–21	1	0–2
C16	Želodec Stomach	M	290	29,2	294	28,9	290	246–335	28	24–33
		Ž	180	17,6	181	17,4	171	137–205	16	13–20
C18	Debelo črevo Colon	M	440	44,2	514	50,5	548	475–621	53	46–61
		Ž	353	34,5	386	37,2	392	335–450	38	32–43
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	364	36,6	409	40,2	430	373–487	42	36–48
		Ž	246	24,0	229	22,1	210	173–247	20	17–24
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	113	11,4	138	13,6	164	130–198	16	13–19
		Ž	44	4,3	51	4,9	57	38–77	6	4–7
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	64	6,5	74	7,3	91	65–116	9	6–11
		Ž	106	10,3	104	10,0	105	77–133	10	7–13
C25	Trebušna slinavka Pancreas	M	154	15,5	183	18,0	229	189–269	22	18–26
		Ž	165	16,1	176	17,0	185	148–221	18	14–21
C32	Grlo Larynx	M	91	9,2	93	9,1	84	59–110	8	6–11
		Ž	11	1,1	12	1,1	13	4–23	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	890	89,6	870	85,5	836	755–917	82	74–89
		Ž	327	31,9	407	39,2	483	427–540	46	41–52
C43	Maligni melanom kože Malignant melanoma of skin	M	194	19,5	262	25,8	343	235–451	33	23–44
		Ž	227	22,2	247	23,8	272	229–315	26	22–30
C44	Druge maligne neoplazme kože Skin, other malignomas	M	898	90,3	1196	117,5	1482	1381–1583	145	135–154
		Ž	975	95,2	1197	115,3	1403	1305–1500	135	125–144
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	28	2,9	28	2,7	30	17–44	3	2–4
		Ž	37	3,6	41	3,9	46	28–63	4	3–6
C50	Dojka Breast	M	8	0,8	13	1,3	18	6–30	2	1–3
		Ž	1149	112,1	1263	121,7	1342	1245–1438	129	120–138
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	152	14,8	128	12,3	101	78–125	10	7–12
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	293	28,6	326	31,4	342	293–390	33	28–37
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	178	17,3	165	15,9	149	118–181	14	11–17
C61	Prostata Prostate	M	1151	115,6	1480	145,5	1812	1693–1931	177	165–188
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	97	9,7	105	10,3	108	81–134	10	8–13
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	206	20,7	245	24,1	272	228–317	27	22–31
		Ž	109	10,7	129	12,4	151	118–185	15	11–18
C67	Sečni mehur Bladder	M	203	20,4	237	23,2	264	220–308	26	21–30
		Ž	76	7,4	81	7,8	93	68–119	9	7–11
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	80	8,0	85	8,4	91	71–111	9	7–11
		Ž	61	6,0	70	6,8	76	53–99	7	5–10
C73	Ščitnica Thyroid gland	M	31	3,1	42	4,1	50	31–70	5	3–7
		Ž	120	11,7	116	11,2	123	94–152	12	9–15
C81	Hodgkinova bolezen Hodgkin's disease	M	27	2,7	23	2,3	19	8–30	2	1–3
		Ž	21	2,0	26	2,5	29	15–43	3	1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	129	13,0	183	18,0	236	195–277	23	19–27
		Ž	142	13,8	177	17,1	208	170–246	20	16–24
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	63	6,3	65	6,4	67	44–90	7	4–9
		Ž	60	5,9	63	6,1	63	41–84	6	4–8
C91–C95	Levkemije Leukaemias	M	147	14,8	159	15,6	174	137–210	17	13–21
		Ž	114	11,2	117	11,3	116	87–145	11	8–14

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2014.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	13753	667,1	327,7	466,2	553,2
		M	7459	730,3	387,8	564,9	681,3
		Ž	6294	605,1	283,2	395,5	462,9
C00–C14	Usta in žrelo Mouth and pharynx	M	279	27,3	15,8	21,9	24,6
		Ž	73	7,0	3,6	5,0	5,7
C15	Požiralnik Oesophagus	M	100	9,8	5,2	7,7	8,9
C16	Želodec Stomach	M	287	28,1	13,7	21,2	25,9
		Ž	166	16,0	6,0	9,0	10,7
C18	Debelo črevo Colon	M	468	45,8	23,1	35,0	43,0
		Ž	343	33,0	12,9	19,2	23,4
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	381	37,3	19,4	28,6	34,4
		Ž	214	20,6	8,2	12,2	14,9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	141	13,8	6,8	10,4	12,8
		Ž	67	6,4	2,6	3,8	4,6
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	96	9,4	4,5	7,1	9,0
		Ž	113	10,9	3,4	5,5	7,0
C25	Trebušna slinavka Pancreas	M	216	21,1	10,8	16,2	19,6
		Ž	181	17,4	6,3	9,6	12,0
C32	Grlo Larynx	M	89	8,7	4,6	6,7	7,9
		Ž	9	0,9	0,5	0,6	0,7
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	889	87,0	45,5	66,8	79,7
		Ž	434	41,7	18,4	26,9	31,2
C43	Maligni melanom kože Malignant melanoma of skin	M	281	27,5	16,3	22,3	26,2
		Ž	235	22,6	13,3	17,3	19,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1213	118,8	58,8	90,0	111,8
		Ž	1220	117,3	46,7	68,3	82,8
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	26	2,5	1,8	2,1	2,4
		Ž	44	4,2	2,4	3,1	3,4
C50	Dojka Breast	M	13	1,3	0,7	1,0	1,1
		Ž	1288	123,8	67,4	91,2	104,0
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	114	11,0	6,8	8,7	9,6
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	356	34,2	16,3	23,3	26,9
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	166	16,0	8,2	11,3	12,9
C61	Prostata Prostate	M	1415	138,5	70,1	104,8	128,9
		Ž	–	–	–	–	–
C62	Modo Testis	M	112	11,0	10,0	10,6	11,5
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	227	22,2	12,3	17,5	20,6
		Ž	145	13,9	5,9	8,6	10,3
C67	Sečni mehur Bladder	M	253	24,8	11,8	18,4	23,2
		Ž	82	7,9	2,6	4,1	5,1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	104	10,2	7,3	8,8	9,3
		Ž	74	7,1	4,7	5,6	6,0
C73	Ščitnica Thyroid gland	M	39	3,8	2,9	3,4	3,8
		Ž	142	13,7	10,2	12,1	13,2
C81	Hodgkinova bolezen Hodgkin's disease	M	24	2,3	2,4	2,4	2,4
		Ž	33	3,2	3,1	3,3	3,5
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	215	21,0	11,8	16,7	19,9
		Ž	182	17,5	7,8	11,2	13,2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	57	5,6	2,9	4,3	5,1
		Ž	53	5,1	1,8	2,7	3,3
C91–C95	Levkemije Leukaemias	M	168	16,4	9,6	13,1	15,6
		Ž	114	11,0	6,5	7,8	8,4

* SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2014.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	13753	12953	94,2	775	5,6	25	0,2
		M	7459	7044	94,4	404	5,4	11	0,1
		Ž	6294	5909	93,9	371	5,9	14	0,2
C00	Ustnica Lip	M	22	22	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C01	Baza jezika Base of tongue	M	21	21	100	0	0	0	0
		Ž	2	2	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	19	19	100	0	0	0	0
		Ž	9	9	—	0	—	0	—
C03	Dlesen Gum	M	4	4	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	32	32	100	0	0	0	0
		Ž	5	5	—	0	—	0	—
C05	Nebo Palate	M	15	15	100	0	0	0	0
		Ž	6	6	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	9	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	11	11	—	0	—	0	—
		Ž	11	11	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	3	3	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C09	Tonzila Tonsil	M	43	43	100	0	0	0	0
		Ž	9	9	—	0	—	0	—
C10	Orofarinks Oropharynx	M	38	38	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	6	6	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	26	26	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	29	29	100	0	0	0	0
		Ž	7	7	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	100	95	95,0	5	5,0	0	0
		Ž	11	10	—	1	—	0	—
C16	Želodec Stomach	M	287	278	96,9	8	2,8	1	0,3
		Ž	166	154	92,8	12	7,2	0	0
C17	Tanko črevo Small intestine	M	27	27	100	0	0	0	0
		Ž	20	19	95,0	1	5,0	0	0
C18	Debelo črevo Colon	M	468	458	97,9	10	2,1	0	0
		Ž	343	328	95,6	13	3,8	2	0,6
C19	Rektosigmoidna zveza Rectosigmoid junction	M	87	85	97,7	2	2,3	0	0
		Ž	61	54	88,5	6	9,8	1	1,6
C20	Rektum Rectum	M	294	290	98,6	3	1,0	1	0,3
		Ž	153	147	96,1	5	3,3	1	0,7
C21	Anus in analni kanal Anus and anal canal	M	4	4	—	0	—	0	—
		Ž	13	12	—	1	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	141	83	58,9	58	41,1	0	0
		Ž	67	37	55,2	30	44,8	0	0
C23	Žolčnik Gallbladder	M	22	14	63,6	8	36,4	0	0
		Ž	46	33	71,7	13	28,3	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	74	53	71,6	21	28,4	0	0
		Ž	67	40	59,7	27	40,3	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti							
				Število Number	%*	Število Number	%*	Število Number	%*						
										Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
										Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	216	137	63,4	76	35,2	3	1,4						
		Ž	181	93	51,4	86	47,5	2	1,1						
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	2	—	0	—	1	—						
		Ž	4	4	—	0	—	0	—						
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	10	9	—	1	—	0	—						
		Ž	8	8	—	0	—	0	—						
C31	Obnosni sinusi Accessory sinuses	M	9	9	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C32	Grlo Larynx	M	89	88	98,9	0	0	1	1,1						
		Ž	9	9	—	0	—	0	—						
C33	Sapnik Trachea	M	1	1	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C34	Sapnica in pljuča Bronchus and lung	M	888	822	92,6	66	7,4	0	0						
		Ž	432	382	88,4	48	11,1	2	0,5						
C37	Timus Thymus	M	6	6	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	3	3	—	0	—	0	—						
		Ž	4	3	—	1	—	0	—						
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—						
		Ž	0	0	—	0	—	0	—						
C40	Kosti, sklepnih hrustanec udov Bone and articular cartilage of limbs	M	3	3	—	0	—	0	—						
		Ž	4	4	—	0	—	0	—						
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	11	11	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C43	Malignni melanom kože Malignant melanoma of skin	M	281	281	100	0	0	0	0						
		Ž	235	235	100	0	0	0	0						
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1213	1191	98,2	22	1,8	0	0						
		Ž	1220	1208	99,0	12	1,0	0	0						
C45	Mezoteliom Mesothelioma	M	28	28	100	0	0	0	0						
		Ž	9	9	—	0	—	0	—						
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	5	—	0	—	0	—						
		Ž	1	1	—	0	—	0	—						
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	2	—	0	—	0	—						
		Ž	2	2	—	0	—	0	—						
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	2	2	—	0	—	0	—						
		Ž	16	16	100	0	0	0	0						
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	24	24	100	0	0	0	0						
		Ž	28	28	100	0	0	0	0						
C50	Dojka Breast	M	13	13	—	0	—	0	—						
		Ž	1288	1279	99,3	6	0,5	3	0,2						
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—						
		Ž	46	46	100	0	0	0	0						
C52	Nožnica Vagina	M	—	—	—	—	—	—	—						
		Ž	10	10	—	0	—	0	—						
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—						
		Ž	114	114	100	0	0	0	0						
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—						
		Ž	356	353	99,2	3	0,8	0	0						
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—						
		Ž	18	17	94,4	0	0	1	5,6						
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—						
		Ž	166	154	92,8	12	7,2	0	0						

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–
		Ž	26	23	88,5	2	7,7	1	3,8
C58	Posteljica Placenta	M	–	–	–	–	–	–	–
		Ž	1	1	–	0	–	0	–
C60	Penis Penis	M	18	18	100	0	0	0	0
		Ž	–	–	–	–	–	–	–
C61	Prostata Prostate	M	1415	1363	96,3	49	3,5	3	0,2
		Ž	–	–	–	–	–	–	–
C62	Modo Testis	M	112	112	100	0	0	0	0
		Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	1	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	214	197	92,1	17	7,9	0	0
		Ž	132	109	82,6	23	17,4	0	0
C65	Ledvični meh Renal pelvis	M	13	11	–	2	–	0	–
		Ž	13	13	–	0	–	0	–
C66	Sečevod Ureter	M	4	4	–	0	–	0	–
		Ž	7	7	–	0	–	0	–
C67	Sečni mehur Bladder	M	253	249	98,4	3	1,2	1	0,4
		Ž	82	80	97,6	2	2,4	0	0
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	5	5	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C69	Oklo in očesni adneksi Eye and adnexa	M	4	4	–	0	–	0	–
		Ž	9	9	–	0	–	0	–
C70	Meninge Meninges	M	1	1	–	0	–	0	–
		Ž	2	1	–	1	–	0	–
C71	Možgani Brain	M	98	87	88,8	11	11,2	0	0
		Ž	71	56	78,9	15	21,1	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	5	5	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C73	Ščitnica Thyroid gland	M	39	39	100	0	0	0	0
		Ž	142	142	100	0	0	0	0
C74	Nadledvična žleza Adrenal gland	M	3	3	–	0	–	0	–
		Ž	6	5	–	1	–	0	–
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	2	–	1	–	0	–
		Ž	25	17	68,0	8	32,0	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	21	20	95,2	1	4,8	0	0
		Ž	7	7	–	0	–	0	–
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	42	21	50,0	21	50,0	0	0
		Ž	40	25	62,5	15	37,5	0	0
C79	Metastaze, drugje Metastases of other sites	M	15	7	46,7	8	53,3	0	0
		Ž	7	4	–	3	–	0	–
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	58	47	81,0	11	19,0	0	0
		Ž	69	44	63,8	24	34,8	1	1,4
C81	Hodgkinova bolezen Hodgkin's disease	M	24	24	100	0	0	0	0
		Ž	33	33	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	47	47	100	0	0	0	0
		Ž	63	63	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	142	142	100	0	0	0	0
		Ž	95	95	100	0	0	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	18	18	100	0	0	0	0
		Ž	10	10	—	0	—	0	—
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	8	8	—	0	—	0	—
		Ž	14	14	—	0	—	0	—
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	57	57	100	0	0	0	0
		Ž	53	53	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	10	10	—	0	—	0	—
		Ž	10	10	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	68	68	100	0	0	0	0
		Ž	41	41	100	0	0	0	0
C92	Mieločna levkemija Myeloid leukaemia	M	67	67	100	0	0	0	0
		Ž	47	47	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	4	4	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	17	17	100	0	0	0	0
		Ž	12	12	—	0	—	0	—
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	81	81	100	0	0	0	0
		Ž	92	92	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	91	91	100	0	0	0	0
		Ž	84	84	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	1	1	—	0	—	0	—
		Ž	109	109	100	0	0	0	0
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III)	M	—	—	—	—	—	—	—
		Ž	1106	1106	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	152	152	100	0	0	0	0
		Ž	49	49	100	0	0	0	0
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	28	23	82,1	5	17,9	0	0
		Ž	49	36	73,5	13	26,5	0	0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	45	45	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	11	5	—	6	—	0	—
		Ž	5	1	—	4	—	0	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2014.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	13753	22	22	13	24	45	79	139	216	303	545	895	1293	1810	1815	1958	1888	2686
		M	7459	13	13	7	18	27	33	54	81	105	225	452	742	1118	1127	1177	1071	1196
		Ž	6294	9	9	6	6	18	46	85	135	198	320	443	551	692	688	781	817	1490
C00	Ustnica Lip	M	22	0	0	0	0	0	0	0	0	1	1	1	4	1	4	2	4	4
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1
C01	Baza jezika Base of tongue	M	21	0	0	0	0	0	0	0	0	1	1	3	6	4	3	1	2	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	19	0	0	0	0	0	0	0	3	1	1	0	3	6	4	1	0	0
		Ž	9	0	0	0	0	0	1	0	0	1	0	2	0	2	2	0	1	0
C03	Dlesen Gum	M	4	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2
C04	Ustno dno Floor of mouth	M	32	0	0	0	0	0	0	0	1	0	4	3	6	6	3	5	4	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	2	2	1	0	0	0	
C05	Nebo Palate	M	15	0	0	0	0	0	0	1	0	0	1	1	2	4	2	3	1	0
		Ž	6	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	1	2
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	0	0	0	0	0	0	0	0	1	2	1	1	0	2	1	0	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	0
C07	Parotidna žleza Parotid gland	M	11	0	0	0	0	0	0	0	0	0	1	2	1	0	2	1	2	2
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2	4
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0
		Ž	2	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
C09	Tonzila Tonsil	M	43	0	0	0	0	0	0	0	0	0	6	5	9	12	6	5	0	0
		Ž	9	0	0	0	0	0	0	0	0	1	0	3	0	1	1	3	0	0
C10	Orofarinks Oropharynx	M	38	0	0	0	0	0	0	0	0	0	5	6	8	5	5	2	3	4
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1
C11	Nazofarinks Nasopharynx	M	6	0	0	0	0	1	0	0	0	0	0	2	2	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	26	0	0	0	0	0	0	0	1	0	1	3	4	10	3	0	3	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	0	0
C13	Hipofarinks Hypopharynx	M	29	0	0	0	0	0	0	0	0	0	2	5	5	7	3	4	1	2
		Ž	7	0	0	0	0	0	0	0	0	0	1	1	0	1	0	2	1	1
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	100	0	0	0	0	0	0	0	0	1	4	11	20	14	16	12	11	11
		Ž	11	0	0	0	0	0	0	0	2	0	0	0	0	3	0	3	0	3
C16	Želodec Stomach	M	287	0	0	0	0	0	0	2	1	2	6	19	42	30	26	50	48	61
		Ž	166	0	0	0	0	1	0	3	1	2	4	9	12	13	18	14	22	67
C17	Tanko črevo Small intestine	M	27	0	0	0	0	0	0	0	0	1	3	1	5	3	5	1	1	7
		Ž	20	0	0	0	0	0	0	0	0	3	0	3	3	0	1	4	3	3
C18	Debelo črevo Colon	M	468	0	0	2	0	0	0	2	1	4	9	35	39	61	71	76	83	85
		Ž	343	0	0	0	0	0	0	3	3	5	8	16	24	37	40	43	62	102
C19	Rektosigmoidna zveza Rectosigmoid junction	M	87	0	0	0	0	0	1	0	0	2	2	7	8	17	16	10	10	14
		Ž	61	0	0	0	0	0	0	0	1	0	1	5	4	4	1	10	13	22
C20	Rektum Rectum	M	294	0	0	0	0	0	0	1	1	5	11	22	29	54	30	56	39	46
		Ž	153	0	0	0	0	0	0	0	4	1	4	12	6	23	14	30	24	35
C21	Anus in analni kanal Anus and anal canal	M	4	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	0	0
		Ž	13	0	0	0	0	0	0	0	0	1	2	1	1	3	0	2	0	3
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	141	0	0	0	0	0	0	1	0	0	4	6	14	22	22	20	25	27
		Ž	67	0	0	0	0	1	0	0	1	0	2	1	4	10	9	10	9	20
C23	Žolčnik Gallbladder	M	22	0	0	0	0	0	0	0	0	1	0	2	2	0	5	3	4	5
		Ž	46	0	0	0	0	0	0	0	0	1	0	2	3	1	4	8	10	17
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	74	0	0	0	0	0	0	0	0	0	0	2	3	7	16	14	20	30
		Ž	67	0	0	0	0	0	0	0	0	0	2	0	3	5	4	9	14	20
C25	Trebšna slinavka Pancreas	M	216	0	0	0	0	0	0	0	1	4	7	14	26	33	29	34	34	34
		Ž	181	0	0	0	0	0	0	3	2	0	2	6	11	15	19	29	35	59
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	2

Nadaljevanje →
Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	10	0	0	0	0	0	0	0	0	0	0	1	0	0	1	4	1	1	2
		Ž	8	0	0	0	1	0	0	0	0	0	0	1	0	1	1	0	0	1	3
C31	Obnosni sinusi Accessory sinuses	M	9	0	0	0	0	0	0	0	0	0	1	1	0	1	0	2	1	1	2
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
C32	Grlo Larynx	M	89	0	0	0	0	0	0	0	1	0	3	3	15	20	15	15	9	8	
		Ž	9	0	0	0	0	0	1	0	0	0	0	0	2	1	2	1	0	2	
C33	Sapnik Trachea	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	
C34	Sapnica in pljuča Bronchus and lung	M	888	0	0	0	0	0	2	1	1	3	20	55	118	174	156	130	130	98	
		Ž	432	0	0	0	0	0	0	0	1	2	6	25	66	70	66	51	68	77	
C37	Timus Thymus	M	6	0	0	0	0	0	0	1	0	1	0	1	0	0	2	1	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	3	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C40	Kosti, sklepnih hrustanec udov Bone and articular cartilage of limbs	M	3	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	
		Ž	4	0	0	1	0	0	0	0	0	0	0	1	0	1	1	0	0	0	
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	11	0	1	1	2	0	1	0	1	0	0	1	1	1	0	1	1	0	
		Ž	2	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	
C43	Malignant melanom kože Malignant melanoma of skin	M	281	0	0	1	2	2	4	4	15	17	18	27	23	32	35	37	29	35	
		Ž	235	0	0	0	1	1	7	8	10	23	25	27	19	11	24	19	27	33	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1213	0	0	0	2	2	2	4	12	22	28	66	87	138	161	205	199	285	
		Ž	1220	1	0	0	0	2	6	10	23	26	50	52	71	113	114	160	182	410	
C45	Mezoteliom Mesothelioma	M	28	0	0	0	0	0	0	1	0	0	0	0	4	8	3	3	5	4	
		Ž	9	0	0	0	0	0	0	0	0	0	1	0	0	3	2	2	0	1	
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	0	0	0	0	0	0	0	1	0	2	0	0	1	1	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
		Ž	2	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	2	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	
		Ž	16	0	0	0	0	0	1	0	0	0	0	0	3	1	2	4	2	3	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	24	1	0	0	1	0	0	0	1	0	3	1	2	4	3	2	4	2	
		Ž	28	1	1	0	0	1	0	1	1	1	2	2	3	1	1	4	6	3	
C50	Dojka Breast	M	13	0	0	0	0	0	0	0	0	0	1	1	3	2	3	1	1	1	
		Ž	1288	0	0	0	0	1	5	23	41	76	126	140	121	156	141	112	175		
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	46	0	0	0	0	0	0	0	0	1	2	1	1	5	5	9	9	13	
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	10	0	0	0	0	0	0	0	1	0	0	1	1	1	1	1	3	1	
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	114	0	0	0	0	0	4	9	11	4	17	10	15	12	5	3	9	15	
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	356	0	0	0	0	0	2	1	7	14	32	50	52	46	58	43	51		
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	18	0	0	0	0	0	0	0	0	0	0	1	3	2	1	3	2	6	
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	166	0	0	0	0	0	3	4	7	15	16	23	14	22	21	10	31		
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	26	0	0	0	0	0	0	0	1	1	0	1	4	2	7	5	1	4	
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0		
C60	Penis Penis	M	18	0	0	0	0	0	0	0	0	0	0	2	1	3	8	2	1	1	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
C61	Prostata Prostate	M	1415	0	0	0	0	0	0	0	0	1	5	47	130	265	282	280	217	188	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	112	0	0	0	2	15	13	21	19	15	13	9	2	2	1	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C64	Ledvica razen meha Kidney, except renal pelvis	M	214	2	0	0	0	0	0	1	4	6	10	15	28	32	36	31	34	
		Ž	132	1	0	0	0	0	0	1	1	3	2	10	11	11	15	19	25	
C65	Ledvični meh Renal pelvis	M	13	0	0	0	0	0	0	0	0	0	0	1	2	2	1	4	0	
		Ž	13	0	0	0	0	0	0	0	0	0	0	1	1	1	4	1	3	
C66	Sečevod Ureter	M	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	
C67	Sečni mehur Bladder	M	253	0	0	0	0	0	0	0	0	0	5	6	14	34	40	46	36	
		Ž	82	0	0	0	0	0	0	0	0	1	0	1	5	7	10	13	11	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	5	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C69	Oklo in očesni adneksi Eye and adnexa	M	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	
		Ž	9	0	1	0	0	0	0	0	0	0	1	0	2	1	0	1	1	
C70	Meninge Meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
C71	Možgani Brain	M	98	4	1	2	1	0	3	4	4	6	4	11	16	16	7	6	9	
		Ž	71	0	4	2	1	1	0	1	1	1	1	10	7	11	9	7	7	
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	5	0	0	0	0	0	0	0	0	1	0	2	0	0	2	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C73	Ščitnica Thyroid gland	M	39	0	0	1	2	3	1	2	3	0	5	4	1	5	2	3	3	
		Ž	142	0	0	1	2	0	12	10	12	19	12	11	13	18	12	10	5	
C74	Nadledvična žleza Adrenal gland	M	3	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	
		Ž	6	0	0	0	0	0	0	0	0	0	0	2	0	1	1	2	0	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
		Ž	25	0	0	0	0	0	0	0	0	0	0	1	2	2	4	1	3	
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	21	0	0	0	0	0	0	0	0	2	1	0	2	2	1	3	4	
		Ž	7	0	0	0	0	0	0	0	0	0	1	1	1	1	0	1	0	
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	42	0	0	0	0	0	0	0	0	0	0	2	2	5	3	8	6	
		Ž	40	0	0	0	0	0	0	0	0	0	0	0	1	2	4	6	7	
C79	Metastaze, drugje Metastases of other sites	M	15	0	0	0	0	0	0	0	0	0	1	1	1	0	0	4	1	
		Ž	7	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	3	
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	58	0	0	0	0	0	0	0	0	1	8	2	8	9	12	7	11	
		Ž	69	0	0	0	0	0	0	1	0	0	0	3	5	6	8	10	13	
C81	Hodgkinova bolezen Hodgkin's disease	M	24	0	4	0	3	1	1	0	2	0	2	2	1	2	0	2	3	
		Ž	33	0	0	0	1	8	3	5	5	1	1	2	1	0	2	1	1	
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	47	0	0	0	0	0	1	1	0	3	1	5	7	9	6	2	4	
		Ž	63	0	0	0	0	0	0	1	1	1	4	9	3	8	9	11	9	
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	142	1	2	0	1	1	1	2	0	2	7	9	13	13	20	28	26	
		Ž	95	0	1	0	0	0	1	1	1	2	1	7	11	10	8	13	17	
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	18	0	0	0	0	0	0	0	0	0	2	2	1	1	3	5	2	
		Ž	10	0	0	0	0	0	0	0	0	1	0	1	0	0	1	3	1	
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	8	0	0	0	0	0	0	0	0	0	1	1	2	0	0	1	2	
		Ž	14	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	

Nadaljevanje →
Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	57	0	0	0	0	0	0	0	1	0	0	4	4	6	10	9	6	4	13
		Ž	53	0	0	0	0	0	1	0	0	0	1	1	5	3	6	7	5	4	24
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	10	2	3	0	1	1	0	0	1	0	0	1	0	1	0	0	0	0	0
		Ž	10	4	2	1	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	68	0	0	0	0	0	0	0	2	0	3	2	4	5	11	11	11	11	19
		Ž	41	0	0	0	0	0	0	0	1	0	2	1	5	2	6	7	4	4	13
C92	Mieloična levkemija Myeloid leukaemia	M	67	1	1	0	0	0	0	2	1	0	3	4	4	7	9	9	11	11	15
		Ž	47	1	0	1	0	1	2	0	0	3	2	2	6	7	5	4	5	8	8
C93	Monocitna levkemija Monocytic leukaemia	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	17	0	0	0	0	0	0	0	0	1	3	2	2	5	0	2	0	0	0
		Ž	12	0	0	0	0	0	0	0	0	0	1	0	1	1	1	2	2	4	0
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	81	0	1	0	0	1	2	1	3	0	3	1	6	8	6	11	15	23	23
		Ž	92	0	0	0	0	0	1	0	3	1	4	3	3	9	7	6	12	15	43

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ Melanoma, in situ	M	91	0	0	0	1	0	4	2	5	8	12	5	11	11	13	9	7	3	3
		Ž	84	0	0	0	0	1	2	4	9	9	12	8	8	4	8	9	8	8	2
D05	Dojka, in situ Breast, in situ	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	109	0	0	0	0	0	0	0	0	4	7	24	23	27	13	3	5	3	3
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III)	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1106	0	0	0	1	110	225	231	199	115	87	44	36	23	14	16	4	1	1
D09.0	Sečni mehur, in situ Bladder, in situ	M	152	0	0	0	0	0	1	1	1	1	3	4	18	26	18	32	22	25	8
		Ž	49	0	0	0	0	0	0	0	0	0	0	0	6	12	5	6	12	8	8
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	28	0	0	0	0	0	0	1	1	0	1	4	5	2	3	5	3	3	3
		Ž	49	0	0	0	0	1	0	1	1	3	6	3	1	7	6	7	7	6	6
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	45	0	0	0	0	2	2	4	3	1	6	7	5	2	2	4	5	2	2
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	11	1	0	0	0	1	0	0	0	0	1	0	1	2	1	0	3	1	1
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	3

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2014.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00–C06	Vse lokacije All sites	M+Ž	667,1	20,0	21,7	14,2	25,1	41,0	58,7	92,0	138,2	206,2	353,2	584,8	852,1	1281,8	1804,0	2129,6	2550,9	2743,8	38,1
		M	730,3	23,0	25,0	14,9	36,5	48,0	47,1	68,1	98,9	137,2	286,4	581,4	966,7	1579,5	2356,3	2873,6	3553,3	4025,7	45,7
		Ž	605,1	16,9	18,2	13,6	12,9	33,7	71,2	118,3	181,4	281,2	422,5	588,3	734,8	982,6	1303,6	1531,8	1862,2	2185,2	31,6
C00	Ustnica Lip	M	2,2	0	0	0	0	0	0	0	0	1,3	1,3	1,3	5,2	1,4	8,4	4,9	13,3	13,5	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	2,3	1,5	0,0
C01	Baza jezika Base of tongue	M	2,1	0	0	0	0	0	0	0	0	1,3	1,3	3,9	7,8	5,7	6,3	2,4	6,6	0	0,1
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	2,3	0	0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	1,9	0	0	0	0	0	0	0	3,7	1,3	1,3	0	3,9	8,5	8,4	2,4	0	0	0,1
		Ž	0,9	0	0	0	0	0	1,5	0	0	1,4	0	2,7	0	2,8	3,8	0	2,3	0	0,1
C03	Dlesen Gum	M	0,4	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	2,1	0	0	3,4	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	2,0	0	2,9	0,0
C04	Ustno dno Floor of mouth	M	3,1	0	0	0	0	0	0	0	1,2	0	5,1	3,9	7,8	8,5	6,3	12,2	13,3	0	0,2
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	2,7	2,7	1,4	0	0	0	0	0,0
C05	Nebo Palate	M	1,5	0	0	0	0	0	0	1,3	0	0	1,3	1,3	2,6	5,7	4,2	7,3	3,3	0	0,1
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	2,7	0	1,4	0	0	2,3	2,9	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	0,9	0	0	0	0	0	0	0	0	1,3	2,5	1,3	1,3	0	4,2	2,4	0	3,4	0,1
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	1,9	2,0	2,3	0	0,0
C07	Parotidna žleza Parotid gland	M	1,1	0	0	0	0	0	0	0	0	0	1,3	2,6	1,3	0	4,2	2,4	6,6	6,7	0,1
		Ž	1,1	0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	1,9	2,0	4,6	5,9	0,0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,4	2,1	2,4	0	0	0,0
		Ž	0,2	0	0	0	0	1,9	0	0	0	0	0	0	0	0	1,9	0	0	0	0,0
C09	Tonzila Tonsil	M	4,2	0	0	0	0	0	0	0	0	0	7,6	6,4	11,7	17,0	12,5	12,2	0	0	0,3
		Ž	0,9	0	0	0	0	0	0	0	0	1,4	0	4,0	0	1,4	1,9	5,9	0	0	0,1
C10	Orofarinks Oropharynx	M	3,7	0	0	0	0	0	0	0	0	0	6,4	7,7	10,4	7,1	10,5	4,9	10,0	13,5	0,2
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	0	2,3	1,5	0,0
C11	Nazofarinks Nasopharynx	M	0,6	0	0	0	1,8	0	0	0	0	0	0	2,6	2,6	0	0	2,4	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0,0
C12	Piriformni sinus Pyiform sinus	M	2,5	0	0	0	0	0	0	0	1,2	0	1,3	3,9	5,2	14,1	6,3	0	10,0	3,4	0,2
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	2,7	1,3	0	1,9	0	0	0	0,0
C13	Hipofarinks Hypopharynx	M	2,8	0	0	0	0	0	0	0	0	0	2,5	6,4	6,5	9,9	6,3	9,8	3,3	6,7	0,2
		Ž	0,7	0	0	0	0	0	0	0	0	0	1,3	1,3	0	1,4	0	3,9	2,3	1,5	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	9,8	0	0	0	0	0	0	0	0	1,3	5,1	14,2	26,1	19,8	33,5	29,3	36,5	37,0	0,6
		Ž	1,1	0	0	0	0	0	0	0	2,7	0	0	0	0	4,3	0	5,9	0	4,4	0,1
C16	Želodec Stomach	M	28,1	0	0	0	0	0	0	2,5	1,2	2,6	7,6	24,4	54,7	42,4	54,4	122,1	159,3	205,3	1,6
		Ž	16,0	0	0	0	0	1,9	0	4,2	1,3	2,8	5,3	12,0	16,0	18,5	34,1	27,5	50,1	98,3	0,6
C17	Tanko črevo Small intestine	M	2,6	0	0	0	0	0	0	0	0	1,3	3,8	1,3	6,5	4,2	10,5	2,4	3,3	23,6	0,2
		Ž	1,9	0	0	0	0	0	0	0	0	4,3	0	4,0	4,0	0	1,9	7,8	6,8	4,4	0,1
C18	Debelo črevo Colon	M	45,8	0	0	4,3	0	0	0	2,5	1,2	5,2	11,5	45,0	50,8	86,2	148,4	185,6	275,4	286,1	2,7
		Ž	33,0	0	0	0	0	0	0	4,2	4,0	7,1	10,6	21,2	32,0	52,5	75,8	84,3	141,3	149,6	1,5

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	8,5	0	0	0	0	0	1,4	0	0	2,6	2,5	9,0	10,4	24,0	33,5	24,4	33,2	47,1	0,5
		Ž	5,9	0	0	0	0	0	0	0	1,3	0	1,3	6,6	5,3	5,7	1,9	19,6	29,6	32,3	0,2
C20	Rektum Rectum	M	28,8	0	0	0	0	0	0	1,3	1,2	6,5	14,0	28,3	37,8	76,3	62,7	136,7	129,4	154,8	1,8
		Ž	14,7	0	0	0	0	0	0	0	5,4	1,4	5,3	15,9	8,0	32,7	26,5	58,8	54,7	51,3	0,8
C21	Anus in analni kanal Anus and anal canal	M	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	2,8	2,1	0	0	0	0,0
		Ž	1,2	0	0	0	0	0	0	0	0	1,4	2,6	1,3	1,3	4,3	0	3,9	0	4,4	0,1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	13,8	0	0	0	0	0	1,3	0	0	5,1	7,7	18,2	31,1	46,0	48,8	82,9	90,9	0,8	
		Ž	6,4	0	0	0	1,9	0	0	1,3	0	2,6	1,3	5,3	14,2	17,1	19,6	20,5	29,3	0,3	
C23	Žolčnik Gallbladder	M	2,2	0	0	0	0	0	0	0	0	1,3	0	2,6	2,6	0	10,5	7,3	13,3	16,8	0,1
		Ž	4,4	0	0	0	0	0	0	0	1,4	0	2,7	4,0	1,4	7,6	15,7	22,8	24,9	0,2	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	7,2	0	0	0	0	0	0	0	0	0	0	2,6	3,9	9,9	33,5	29,3	46,4	67,3	0,4
		Ž	6,4	0	0	0	0	0	0	0	0	0	2,6	0	4,0	7,1	7,6	17,7	31,9	44,0	0,2
C25	Trebušna slinavka Pancreas	M	21,1	0	0	0	0	0	0	1,2	5,2	8,9	18,0	33,9	46,6	60,6	83,0	112,8	114,4	1,3	
		Ž	17,4	0	0	0	0	0	4,2	2,7	0	2,6	8,0	14,7	21,3	36,0	56,9	79,8	86,5	0,7	
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,3	0	0	0	0	0	0	0	0	0	0	0	1,4	2,1	0	0	3,4	0,0	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,3	2,9	0,0	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	1,0	0	0	0	0	0	0	0	0	0	1,3	0	0	1,4	8,4	2,4	3,3	6,7	0,1
		Ž	0,8	0	0	2,2	0	0	0	0	0	0	1,3	0	1,3	1,4	0	0	2,3	4,4	0,0
C31	Obnosni sinusi Accessory sinuses	M	0,9	0	0	0	0	0	0	0	0	1,3	1,3	0	1,3	0	4,2	2,4	3,3	6,7	0,1
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	1,4	0	0	0	0	0,0
C32	Grlo Larynx	M	8,7	0	0	0	0	0	0	1,2	0	3,8	3,9	19,5	28,3	31,4	36,6	29,9	26,9	0,6	
		Ž	0,9	0	0	0	0	1,5	0	0	0	0	0	2,7	1,4	3,8	2,0	0	2,9	0,1	
C33	Sapnik Trachea	M	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	2,3	0	0,0	
C34	Sapnica in pljuča Bronchus and lung	M	86,9	0	0	0	0	2,9	1,3	1,2	3,9	25,5	70,8	153,7	245,8	326,2	317,4	431,3	329,9	5,7	
		Ž	41,5	0	0	0	0	0	0	1,3	2,8	7,9	33,2	88,0	99,4	125,1	100,0	155,0	112,9	2,3	
C37	Timus Thymus	M	0,6	0	0	0	0	0	1,3	0	1,3	0	1,3	0	0	4,2	2,4	0	0	0,1	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,6	0	0,0	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,3	0	0	0	0	0	1,3	0	0	1,3	0	0	0	0	2,4	0	0	0,0	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	1,4	1,9	2,0	0	1,5	0,0	
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,3	0	0	0	2,0	0	0	0	1,2	0	1,3	0	0	0	0	0	0	0	0,0
		Ž	0,4	0	2,3	0	0	0	0	0	0	0	0	1,3	0	1,4	1,9	0	0	0	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	1,1	0	1,9	2,1	4,1	0	1,4	0	1,2	0	0	1,3	1,3	1,4	0	2,4	3,3	0	0,1
		Ž	0,2	0	0	0	0	0	0	0	1,3	0	1,3	0	0	0	0	0	0	0	0
C43	Malignni melanom kože Malignant melanoma of skin	M	27,5	0	0	2,1	4,1	3,6	5,7	5,0	18,3	22,2	22,9	34,7	30,0	45,2	73,2	90,3	96,2	117,8	1,8
		Ž	22,6	0	0	0	2,2	1,9	10,8	11,1	13,4	32,7	33,0	35,9	25,3	15,6	45,5	37,3	61,5	48,4	1,3
C44	Druge maligne neoplazme kože Skin, other malignomas	M	118,8	0	0	0	4,1	3,6	2,9	5,0	14,7	28,8	35,6	84,9	113,3	195,0	336,6	500,5	660,2	959,3	6,6
		Ž	117,3	1,9	0	0	0	3,7	9,3	13,9	30,9	36,9	66,0	69,1	94,7	160,5	216,0	313,8	414,8	601,3	5,1
C45	Mezoteliom Mesothelioma	M	2,7	0	0	0	0	0	0	1,3	0	0	0	0	5,2	11,3	6,3	7,3	16,6	13,5	0,2
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	1,3	0	0	4,3	3,8	3,9	0	1,5
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,5	0	0	0	0	0	0	0	1,2	0	2,5	0	0	1,4	2,1	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,5
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0,2	1,8	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0,0
		Ž	0,2	1,9	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,2	0	0	0	0	0	1,4	0	0	0	0	0	0	0	2,1	0	0	0	0,0
		Ž	1,5	0	0	0	0	0	1,5	0	0	0	0	0	4,0	1,4	3,8	7,8	4,6	4,4	0,1
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	2,3	1,8	0	0	2,0	0	0	0	1,2	0	3,8	1,3	2,6	5,7	6,3	4,9	13,3	6,7	0,1
		Ž	2,7	1,9	2,0	0	0	1,9	0	1,4	1,3	1,4	2,6	2,7	4,0	1,4	1,9	7,8	13,7	4,4	0,2
C50	Dojka Breast	M	1,3	0	0	0	0	0	0	0	0	0	1,3	1,3	3,9	2,8	6,3	2,4	3,3	3,4	0,1
		Ž	123,8	0	0	0	0	1,9	7,7	32,0	55,1	107,9	166,4	185,9	161,4	242,8	295,6	276,6	255,3	256,7	7,7
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	4,4	0	0	0	0	0	0	0	0	1,4	2,6	1,3	1,3	7,1	9,5	17,7	20,5	19,1	0,2
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1,0	0	0	0	0	0	0	0	1,3	0	0	1,3	1,3	1,4	1,9	2,0	6,8	1,5	0,0
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	11,0	0	0	0	0	0	6,2	12,5	14,8	5,7	22,4	13,3	20,0	17,0	9,5	5,9	20,5	22,0	0,6
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	34,2	0	0	0	0	0	0	2,8	1,3	9,9	18,5	42,5	66,7	73,8	87,2	113,8	98,0	74,8	2,1
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1,7	0	0	0	0	0	0	0	0	0	0	1,3	4,0	2,8	1,9	5,9	4,6	8,8	0,1
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	16,0	0	0	0	0	0	0	4,2	5,4	9,9	19,8	21,2	30,7	19,9	41,7	41,2	22,8	45,5	1,0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	2,5	0	0	0	0	0	0	0	1,3	1,4	0	1,3	5,3	2,8	13,3	9,8	2,3	5,9	0,2
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	0,1	0	0	0	0	0	1,5	0	0	0	0	0	0	0	0	0	0	0	0,0
C60	Penis Penis	M	1,8	0	0	0	0	0	0	0	0	0	0	2,6	1,3	4,2	16,7	4,9	3,3	3,4	0,1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C61	Prostata Prostate	M	138,5	0	0	0	0	0	0	0	0	1,3	6,4	60,5	169,4	374,4	589,6	683,6	719,9	632,8	9,4
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	11,0	0	0	0	4,1	26,7	18,6	26,5	23,2	19,6	16,5	11,6	2,6	2,8	2,1	0	0	0	0,8
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,3	0	0,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	21,0	3,5	0	0	0	0	0	1,3	4,9	7,8	12,7	19,3	36,5	45,2	75,3	75,7	112,8	50,5	1,4
		Ž	12,7	1,9	0	0	0	0	0	1,4	1,3	4,3	2,6	13,3	14,7	15,6	28,4	37,3	57,0	48,4	0,6
C65	Ledvični meh Renal pelvis	M	1,3	0	0	0	0	0	0	0	0	0	0	1,3	2,6	2,8	2,1	9,8	0	10,1	0,1
		Ž	1,2	0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	7,6	2,0	6,8	2,9	0,1
C66	Sečevod Ureter	M	0,4	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0	2,4	0	6,7	0,0
		Ž	0,7	0	0	0	0	0	0	0	0	0	0	0	2,7	1,4	0	2,0	0	4,4	0,0
C67	Sečni mehur Bladder	M	24,8	0	0	0	0	0	0	0	0	0	6,4	7,7	18,2	48,0	83,6	112,3	119,4	242,4	1,4
		Ž	7,9	0	0	0	0	0	0	0	0	1,4	0	1,3	6,7	9,9	18,9	25,5	25,1	49,9	0,3
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,5	0	0	0	0	0	0	0	0	0	0	0	0	2,8	2,1	2,4	0	3,4	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	1,4	0	0	3,3	3,4	0,0
		Ž	0,9	0	2,0	0	0	0	0	0	0	0	1,3	0	2,7	1,4	0	2,0	2,3	2,9	0,0
C70	Meninge Meninges	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	1,5	0,0
C71	Možgani Brain	M	9,6	7,1	1,9	4,3	2,0	0	4,3	5,0	4,9	7,8	5,1	14,2	20,8	22,6	14,6	14,6	29,9	13,5	0,6
		Ž	6,8	0	8,1	4,5	2,2	1,9	0	1,4	1,3	1,4	1,3	13,3	9,3	15,6	17,1	13,7	16,0	11,7	0,5
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	0,5	0	0	0	0	0	0	0	0	1,3	0	2,6	0	0	4,2	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0,0
C73	Ščitnica Thyroid gland	M	3,8	0	0	2,1	4,1	5,3	1,4	2,5	3,7	0	6,4	5,1	1,3	7,1	4,2	7,3	10,0	13,5	0,3
		Ž	13,7	0	0	2,3	4,3	0	18,6	13,9	16,1	27,0	15,8	14,6	17,3	25,6	22,7	19,6	11,4	7,3	1,0
C74	Nadledvična žleza Adrenal gland	M	0,3	1,8	0	0	0	0	0	0	0	0	0	0	0	0	2,1	0	3,3	0	0,0
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	2,7	0	1,9	2,0	4,6	0	0,0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	2,1	2,4	0	3,4	0,0
		Ž	2,4	0	0	0	0	0	0	0	0	0	0	1,3	2,7	2,8	7,6	2,0	6,8	17,6	0,1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	2,1	0	0	0	0	0	0	0	0	2,6	1,3	0	2,6	2,8	2,1	7,3	13,3	20,2	0,1
		Ž	0,7	0	0	0	0	0	0	0	0	0	1,3	1,3	1,3	1,4	0	2,0	0	2,9	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C78	Metastaze dihal in prebavil	M	4,1	0	0	0	0	0	0	0	0	0	0	2,6	2,6	7,1	6,3	19,5	19,9	53,9	0,2
	Metastases of respiratory and digestive organs	Ž	3,8	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	7,6	11,8	16,0	29,3	0,1
C79	Metastaze, drugje	M	1,5	0	0	0	0	0	0	0	0	0	1,3	1,3	1,3	0	0	9,8	3,3	23,6	0,1
	Metastases of other sites	Ž	0,7	0	0	0	0	0	0	0	0	1,4	0	0	0	0	1,9	2,0	2,3	4,4	0,0
C80	Maligna neoplazma brez opredeljenega mesta	M	5,7	0	0	0	0	0	0	0	0	0	1,3	10,3	2,6	11,3	18,8	29,3	23,2	37,0	0,4
	Malignant neoplasm without specification of site	Ž	6,6	0	0	0	0	0	0	1,4	0	0	0	4,0	6,7	8,5	15,2	19,6	29,6	33,7	0,3
C81	Hodgkinova bolezen	M	2,3	0	7,7	0	6,1	1,8	1,4	0	2,4	0	2,5	2,6	1,3	2,8	0	4,9	10,0	3,4	0,2
	Hodgkin's disease	Ž	3,2	0	0	0	2,2	15,0	4,6	7,0	6,7	1,4	1,3	2,7	1,3	0	3,8	2,0	2,3	2,9	0,2
C82	Folikularni ne-Hodgkinov limfom	M	4,6	0	0	0	0	1,4	1,3	0	3,9	1,3	6,4	9,1	12,7	12,5	4,9	13,3	26,9	0,3	
	Follicular non-Hodgkin's lymphoma	Ž	6,1	0	0	0	0	0	1,4	1,3	1,4	5,3	12,0	4,0	11,4	17,1	21,6	20,5	10,3	0,4	
C83	Difuzni ne-Hodgkinov limfom	M	13,9	1,8	3,8	0	2,0	1,8	1,4	2,5	0	2,6	8,9	11,6	16,9	18,4	41,8	68,4	86,3	53,9	0,9
	Diffuse non-Hodgkin's lymphoma	Ž	9,1	0	2,0	0	0	0	1,5	1,4	1,3	2,8	1,3	9,3	14,7	14,2	15,2	25,5	38,7	32,3	0,4
C84	Limfomi celic T in kožni limfom celic T	M	1,8	0	0	0	0	0	0	0	0	2,5	2,6	1,3	1,4	6,3	12,2	6,6	6,7	0,1	
	Peripheral and cutaneous T-cell lymphomas	Ž	1,0	0	0	0	0	0	0	0	1,3	0	1,3	1,3	0	0	1,9	5,9	2,3	2,9	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	0,8	0	0	0	0	0	0	0	0	1,3	1,3	2,6	0	0	2,4	6,6	3,4	0,0	
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,3	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	0	4,6	14,7	0,0	
C88	Maligne imunoproliferativne bolezni	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Malignant immunoproliferative diseases	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,5	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	5,6	0	0	0	0	0	1,3	0	0	5,1	5,1	7,8	14,1	18,8	14,6	13,3	43,8	0,3	
	Multiple myeloma and malignant plasma cell neoplasms	Ž	5,1	0	0	0	0	1,5	0	0	0	1,3	1,3	6,7	4,3	11,4	13,7	11,4	35,2	0,2	
C91.0	Limfatična levkemija, akutna	M	1,0	3,5	5,8	0	2,0	1,8	0	0	1,2	0	0	1,3	0	1,4	0	0	0	0	0,1
	Lymphoblastic leukaemia, acute	Ž	1,0	7,5	4,1	2,3	0	0	0	0	0	0	0	0	0	2,8	0	0	2,3	0	0,1
C91.1 – C91.9	Limfatična levkemija, druga	M	6,7	0	0	0	0	0	0	2,4	0	3,8	2,6	5,2	7,1	23,0	26,9	36,5	64,0	0,4	
	Lymphoid leukaemia, other	Ž	3,9	0	0	0	0	0	0	0	1,3	0	2,6	1,3	6,7	2,8	11,4	13,7	9,1	19,1	0,2
C92	Mieloična levkemija	M	6,6	1,8	1,9	0	0	0	2,5	1,2	0	3,8	5,1	5,2	9,9	18,8	22,0	36,5	50,5	0,4	
	Myeloid leukaemia	Ž	4,5	1,9	0	2,3	0	1,9	3,1	0	0	4,3	2,6	2,7	8,0	9,9	9,5	7,8	11,4	11,7	0,3
C93	Monocitna levkemija	M	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,4	0	6,7	0,0	
	Monocytic leukaemia	Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,0	0	0	0,0	

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C94	Druge opredeljene levkemije	M	1,7	0	0	0	0	0	0	0	0	1,3	3,8	2,6	2,6	2,8	10,5	0	6,6	0	0,1
	Other leukaemias of specified cells	Ž	1,2	0	0	0	0	0	0	0	0	0	1,3	0	1,3	1,4	1,9	3,9	4,6	5,9	0,0
C95	Levkemija z neopredeljenim celičnim tipom	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,3	3,4	0,0
	Leukaemia, unspecified cell type	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,9	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	7,9	0	1,9	0	0	1,8	2,9	1,3	3,7	0	3,8	1,3	7,8	11,3	12,5	26,9	49,8	77,4	0,4
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	8,8	0	0	0	0	1,5	0	4,0	1,4	5,3	4,0	4,0	12,8	13,3	11,8	27,4	63,1	0,3	

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ	M	8,9	0	0	0	2,0	0	5,7	2,5	6,1	10,5	15,3	6,4	14,3	15,5	27,2	22,0	23,2	10,1	0,6
	Melanoma, in situ	Ž	8,1	0	0	0	1,9	3,1	5,6	12,1	12,8	15,8	10,6	10,7	5,7	15,2	17,7	18,2	2,9	0,6	
D05	Dojka, in situ	M	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0,0
	Breast, in situ	Ž	10,5	0	0	0	0	0	0	0	0	5,7	9,2	31,9	30,7	38,3	24,6	5,9	11,4	4,4	0,7
D06	Maternični vrat, in situ (CIN III)	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri, in situ (CIN III)	Ž	106,3	0	0	0	2,2	205,9	348,3	321,5	267,4	163,3	114,9	58,4	48,0	32,7	26,5	31,4	9,1	1,5	8,1
D09.0	Sečni mehur, in situ	M	14,9	0	0	0	0	0	1,4	1,3	1,2	1,3	3,8	5,1	23,5	36,7	37,6	78,1	73,0	84,1	1,0
	Bladder, in situ	Ž	4,7	0	0	0	0	0	0	0	0	0	0	0	8,0	17,0	9,5	11,8	27,4	11,7	0,2
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja	M	2,7	0	0	0	0	0	0	1,3	1,2	0	1,3	5,1	6,5	2,8	6,3	12,2	10,0	10,1	0,2
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	4,7	0	0	0	0	1,9	0	1,4	1,3	4,3	7,9	4,0	1,3	9,9	11,4	13,7	16,0	8,8	0,3
D33.0 – D33.2	Možgani, benigna neoplazma	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Benign neoplasm of brain	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary, neopl. of uncertain behavior	Ž	4,3	0	0	0	0	3,7	3,1	5,6	4,0	1,4	7,9	9,3	6,7	2,8	3,8	7,8	11,4	2,9	0,3
D43.0 – D43.2	Možgani, neopredeljeno	M	1,1	1,8	0	0	0	1,8	0	0	0	0	1,3	0	1,3	2,8	2,1	0	10,0	3,4	0,1
	CNS, uncertain or unknown	Ž	0,5	0	0	0	0	0	0	0	0	0	1,3	0	0	1,4	0	0	0	4,4	0,0

Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2014.

Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenia, total	Statistična regija / Statistical region											
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Spodnjeposavska	Jugovzhodna Slovenija	Osrjednjeslovenska	Gorenjska	Notranjsko-kraška	Goriška	Obalno-kraška
C00–C96	Vse lokacije All sites	M+Ž	13753	908	1974	483	1568	322	474	1054	3714	1365	330	840	721
		M	7459	536	1063	264	835	174	279	561	1945	739	192	485	386
		Ž	6294	372	911	219	733	148	195	493	1769	626	138	355	335
		M	279	27	58	15	32	11	20	24	46	16	11	7	12
C00–C14	Usta in žrelo Mouth and pharynx	Ž	73	7	9	2	10	3	0	5	21	6	4	3	3
		M	100	6	19	7	9	4	5	8	18	10	5	5	4
C15	Požiralnik Esophagus	Ž	11	0	2	1	1	0	0	1	4	2	0	0	0
		M	287	23	56	10	49	12	13	15	55	23	9	12	10
C16	Želodec Stomach	Ž	166	17	39	5	17	5	6	7	26	23	0	10	11
		M	468	29	61	10	56	11	21	35	119	53	11	39	23
C18	Debelo črevo Colon	Ž	343	11	53	12	48	8	9	30	93	37	7	21	14
		M	381	32	60	16	44	12	11	26	96	28	11	31	14
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	214	18	34	10	26	16	10	10	53	14	2	12	9
		M	141	9	23	4	14	3	2	13	35	11	2	12	13
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	67	2	14	6	6	0	2	5	13	5	0	6	8
		M	96	6	22	3	10	4	2	5	24	11	2	4	3
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	113	7	14	4	12	5	3	7	24	20	2	9	6
		M	216	8	38	5	23	5	6	14	64	24	5	11	13
C25	Trebušna slinavka Pancreas	Ž	181	9	23	6	27	4	3	12	49	22	7	9	10
		M	89	2	22	5	12	1	8	7	20	4	3	2	3
C32	Grlo Larynx	Ž	9	1	2	1	2	1	0	0	2	0	0	0	0
		M	889	55	139	41	95	35	26	62	217	101	17	52	49
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	434	16	74	13	43	12	6	40	133	39	9	28	21
		M	281	9	33	4	28	6	9	20	98	33	5	18	18
C43	Maligni melanom kože Malignant melanoma of skin	Ž	235	17	27	5	31	7	4	17	71	24	8	10	14
		M	1213	86	116	43	120	13	46	118	376	121	21	72	81
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	1220	95	120	63	126	18	43	111	380	107	24	73	60
		M	26	2	3	1	3	0	1	6	5	2	0	1	2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	Ž	44	6	7	1	8	1	0	2	7	3	3	3	3
		M	13	1	3	1	1	0	0	2	1	2	1	0	1
C50	Dojka Breast	Ž	1288	70	209	32	136	25	44	105	371	126	33	67	70
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C53	Maternični vrat Cervix uteri	Ž	114	4	24	8	15	2	6	10	20	11	0	8	6
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C54	Maternično telo Corpus uteri	Ž	356	27	60	10	51	6	4	20	91	41	8	15	23
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C56	Jajčnik Ovary	Ž	166	7	28	7	20	2	7	14	34	20	6	10	11
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
		M	1415	162	197	57	165	14	58	92	328	132	43	102	65
C62	Modo Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
		M	112	7	14	7	11	4	1	6	38	7	5	6	6
C64–C65	Ledvica z ledvičnim mehonom Kidney with renal pelvis	Ž	145	8	24	2	18	3	5	9	39	17	4	11	5
		M	227	20	36	8	18	7	16	15	54	18	8	15	12
C67	Sečni mehur Bladder	Ž	82	4	13	4	7	3	4	5	25	5	2	5	5
		M	253	12	42	9	25	5	9	15	78	36	7	11	4
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	74	2	10	2	11	5	2	4	24	8	0	3	3
		M	104	6	21	3	12	0	4	11	27	12	1	2	5
C73	Ščitnica Thyroid gland	Ž	142	7	8	3	35	3	7	11	38	8	1	10	11
		M	39	0	7	0	4	1	3	0	14	4	0	4	2
C81	Hodgkinova bolezen Hodgkin's disease	Ž	33	4	4	2	4	0	1	2	10	1	0	1	4
		M	24	2	5	0	2	0	1	1	9	1	0	3	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	182	11	31	5	23	2	2	13	52	19	3	9	12
		M	215	5	25	4	37	8	4	20	47	21	9	21	14
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	53	0	8	0	4	1	2	4	16	10	0	3	5
		M	57	1	7	1	6	1	2	4	18	6	0	7	4
C91–C95	Levkemije Leukaemias	Ž	114	2	16	2	11	5	4	11	39	12	3	4	5
		M	168	9	25	1	17	5	2	9	51	25	3	11	10

Tabela 6b: Starostno standardizirana* incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2014.

Table 6b: Age standardised* incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenija, total	Statistična regija / Statistical region												
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Spodnjeposavska	Jugovzhodna Slovenija	Osejnslovenska	Gorenjska	Notranjsko-kraška	Goriška	Obalno-kraška	
C00–C96	Vse lokacije All sites	M+Ž	553,2	607,8	486,5	550,0	513,6	582,5	554,6	634,8	593,7	558,2	514,8	542,9	509,0	
		M	681,3	832,7	599,2	657,2	610,8	720,4	726,3	774,9	713,1	688,8	643,8	705,3	606,2	
C00–C14	Usta in žrelo Mouth and pharynx	Ž	462,9	451,5	404,1	461,6	441,2	489,2	423,9	535,2	514,9	466,4	397,1	429,8	453,8	
		M	24,6	39,8	31,8	35,0	22,2	39,0	51,4	30,9	16,7	14,9	33,2	10,1	19,7	
C15	Požiralnik Oesophagus	Ž	5,7	10,0	5,1	5,8	6,1	10,1	0,0	6,1	6,2	3,8	11,6	4,0	4,8	
		M	8,9	8,7	10,6	16,5	6,6	13,7	12,1	9,9	6,5	8,9	15,2	6,7	7,1	
C16	Želodec Stomach	Ž	0,8	0,0	0,9	2,2	0,7	0,0	0,0	0,6	1,3	1,2	0,0	0,0	0,0	
		M	25,9	35,2	31,9	24,8	36,0	49,7	31,8	20,3	20,1	20,3	28,7	17,1	13,9	
C18	Debelo črevo Colon	Ž	10,7	17,7	14,4	9,3	9,3	14,0	10,3	5,2	7,1	16,4	0,0	9,1	15,9	
		M	43,0	43,8	34,4	24,6	42,0	42,2	56,7	49,4	43,9	50,5	36,2	55,4	34,6	
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	23,4	12,9	23,5	23,0	26,3	26,4	22,2	30,3	25,6	22,6	18,3	21,5	16,2	
		M	34,4	50,3	34,0	37,9	32,4	48,0	28,2	34,3	34,7	26,1	34,6	43,6	22,4	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	14,9	20,5	14,6	21,6	13,7	47,5	22,2	8,7	15,0	10,2	6,7	12,9	12,3	
		M	12,8	15,2	12,9	9,0	10,0	13,8	5,4	18,4	12,8	9,8	7,6	17,5	20,3	
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	4,6	2,7	6,3	13,3	3,4	0,0	4,8	4,3	3,4	3,5	0,0	5,8	9,8	
		M	9,0	9,9	13,0	8,0	7,6	15,4	4,9	7,8	8,7	10,7	7,7	6,2	4,8	
C25	Trebušna slinavka Pancreas	Ž	7,0	6,4	5,3	8,1	6,3	14,0	5,8	6,1	6,0	11,8	2,7	9,6	6,4	
		M	19,6	11,0	20,9	12,1	16,8	22,8	16,2	18,2	23,2	22,0	15,9	15,5	21,5	
C32	Grlo Larynx	Ž	12,0	8,7	8,8	13,9	14,3	10,8	6,7	13,8	12,2	16,0	15,0	10,6	12,5	
		M	7,9	2,6	12,2	10,7	8,4	4,3	20,8	9,3	7,0	3,3	9,3	3,4	4,3	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	0,7	2,2	0,7	2,6	1,3	3,3	0,0	0,0	0,5	0,0	0,0	0,0	0,0	
		M	79,7	82,5	74,7	98,1	68,6	144,7	66,7	82,4	79,6	92,4	55,1	74,9	74,5	
C43	Maligni melanom kože Malignant melanoma of skin	Ž	31,2	16,6	33,1	26,8	24,4	35,6	14,7	45,1	37,8	29,7	23,4	34,1	26,4	
		M	26,2	14,1	18,8	10,1	20,8	22,4	23,3	28,4	36,4	32,1	18,1	28,9	28,6	
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	19,8	22,1	13,2	13,7	20,0	38,6	10,8	19,4	23,6	20,8	29,1	13,4	23,0	
		M	111,8	139,7	65,7	107,1	88,2	57,0	123,2	164,3	137,2	113,5	72,6	105,8	129,4	
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	Ž	82,8	107,7	47,6	127,5	69,5	50,3	81,0	110,3	103,8	74,6	61,4	76,6	75,9	
		M	2,4	3,6	2,1	2,9	2,2	0,0	2,0	8,0	1,9	2,1	0,0	1,5	2,3	
C50	Dojka Breast	Ž	3,4	8,3	3,4	1,2	5,8	3,9	0,0	2,6	2,2	2,7	8,9	1,6	4,8	
		M	1,1	1,8	1,5	2,8	0,8	0,0	0,0	2,6	0,4	1,8	2,7	0,0	1,2	
C53	Maternični vrat Cervix uteri	Ž	104,0	97,4	98,5	76,9	88,9	93,9	103,9	127,5	117,0	106,0	109,6	95,7	99,2	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C54	Maternično telo Corpus uteri	Ž	9,6	5,5	12,9	18,2	9,4	7,9	13,5	11,3	6,6	10,0	0,0	13,6	8,9	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C56	Jajčnik Ovary	Ž	26,9	32,3	26,8	22,5	31,8	18,1	7,4	21,6	27,7	32,1	24,6	20,0	30,9	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C61	Prostata Prostate	Ž	12,9	9,0	13,5	16,0	12,7	6,5	17,1	16,1	10,4	15,5	22,4	10,1	16,0	
		M	128,9	247,1	109,7	146,3	120,2	59,6	148,6	131,0	121,5	123,0	143,5	146,6	103,2	
C62	Modo Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	
		M	11,5	12,9	9,1	23,2	8,6	23,7	2,7	9,7	14,2	7,7	18,6	11,0	11,0	
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	
		M	20,6	29,1	20,6	19,4	12,9	27,4	41,1	21,3	19,8	17,0	26,7	21,2	20,6	
C67	Sečni mehur Bladder	Ž	10,3	10,1	9,2	4,5	10,1	6,6	10,6	10,2	11,3	13,3	10,4	14,0	4,4	
		M	23,2	19,0	24,2	22,6	18,9	21,2	24,9	20,9	28,6	32,3	24,6	15,6	5,2	
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	5,1	3,0	4,9	6,2	4,3	6,6	9,9	4,0	6,1	3,1	4,7	6,3	4,9	
		M	9,3	9,5	11,6	8,1	8,5	0,0	9,6	14,3	9,6	11,7	4,9	2,3	7,6	
C73	Ščitnica Thyroid gland	Ž	6,0	4,2	5,2	4,3	7,0	18,1	4,8	4,6	7,3	7,3	0,0	2,8	4,1	
		M	3,8	0,0	4,8	0,0	2,8	4,8	9,1	0,0	5,4	4,1	0,0	6,3	2,4	
C81	Hodgkinova bolezen Hodgkin's disease	Ž	13,2	9,0	4,6	7,6	26,2	14,4	20,5	16,4	13,4	7,8	3,3	17,8	16,4	
		M	2,4	5,2	3,3	0,0	1,7	0,0	2,0	1,4	3,4	1,1	0,0	4,7	0,0	
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	3,5	8,8	2,4	2,4	4,4	0,0	2,6	2,5	3,7	1,1	0,0	3,5	8,5	
		M	19,9	8,2	14,4	11,1	27,2	32,4	10,0	26,5	17,2	20,0	35,0	30,9	22,7	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	13,2	12,4	15,3	8,3	13,9	7,2	3,7	14,2	14,5	12,8	8,5	10,8	17,5	
		M	5,1	1,1	4,1	2,6	4,4	4,0	5,8	5,8	6,4	5,5	0,0	9,4	5,3	
C91–C95	Levkemije Leukaemias	Ž	3,3	0,0	2,8	0,0	1,9	3,5	4,9	3,2	4,2	5,8	0,0	1,6	6,7	
		M	15,6	14,6	15,0	2,8	12,2	23,6	5,1	13,3	18,6	23,4	9,6	17,8	15,4	

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2014.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2014.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
	C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09					
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C				
Vse vrste/All types	12303	650	25	0	22	1	28	0	8	0	37	0	21	0	14	1	22	0	5	0	51	1				
Small cell carcinoma	195	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Squamous cell carcinoma	1379	61	25	0	22	1	27	0	6	0	36	0	15	0	11	0	1	0	0	0	49	1				
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Adenocarcinoma	6223	215	0	0	0	0	0	0	2	0	0	0	3	0	1	0	9	0	3	0	0	0				
Other specified carcinomas	89	7	0	0	0	0	0	0	0	0	1	0	3	0	2	1	11	0	1	0	0	0				
Carcinoma, unspecified	105	166	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0				
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0				
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12303	650	40	2	7	0	30	0	35	1	1	0	105	0	429	3	46	0	782	4	139	0		
Small cell carcinoma	195	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0		
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Squamous cell carcinoma	1379	61	39	0	6	0	29	0	35	1	1	0	81	0	1	0	0	0	0	0	0	0		
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Adenocarcinoma	6223	215	0	0	0	0	0	0	0	0	0	0	23	0	399	0	31	0	766	4	137	0		
Other specified carcinomas	89	7	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	3	0	1	0		
Carcinoma, unspecified	105	166	1	2	0	0	1	0	0	0	0	0	0	0	7	3	2	0	9	0	1	0		
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0		
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	21	0	12	0	2	0	0	0		
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C06		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	12303	650	437	0	16	0	104	16	45	2	73	20	174	56	5	1	16	1	10	1	96	1				
Small cell carcinoma	195	29	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	1	0		
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Squamous cell carcinoma	1379	61	1	0	11	0	0	0	0	0	0	0	0	0	0	0	6	0	6	1	88	1				
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Transitional cell carcinoma	333	5	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Adenocarcinoma	6223	215	430	0	3	0	102	16	41	1	65	13	159	33	5	1	3	0	2	0	0	0	0	0		
Other specified carcinomas	89	7	0	0	0	0	0	0	1	0	2	0	1	2	0	0	1	0	1	0	1	0	0	0		
Carcinoma, unspecified	105	166	4	0	0	0	0	0	2	1	5	4	9	21	0	0	3	0	0	0	4	0				
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant melanoma	548	4	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0		
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0		
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Angiosarcoma	9	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0		
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant complex mixed and stromal tumors	78	0	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0		
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	1	3	2	0	0	0	0	0	0	0	0	0	0	0		

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																						
			C00–C06		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45		
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	
Vse vrste/All types	12303	650	3	0	1025	179	7	1	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Small cell carcinoma	195	29	0	0	176	26	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Non-small cell carcinoma	58	31	0	0	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1379	61	2	0	313	29	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	385	24	0	0
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1928	21	0	0
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6223	215	1	0	443	79	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	17	0	0	0
Other specified carcinomas	89	7	0	0	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	105	166	0	0	7	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	5	0	0
Malignant thymoma	5	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	516	0	0	0
Fibrosarcoma	11	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	9	0	0	0	0	0	0	0	2	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	4	0	2	0	0	0	0	0	0	0	0	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	36	1
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	11	7	0	0	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	12303	650	6	0	4	0	18	0	51	1	1183	109	46	0	10	0	114	0	352	1	17	0		
Small cell carcinoma	195	29	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1379	61	0	0	0	0	0	0	0	0	0	0	0	37	0	7	0	89	0	2	0	1	0	
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Adenocarcinoma	6223	215	0	0	0	0	12	0	0	0	1161	33	1	0	1	0	22	0	317	0	0	0	0	
Other specified carcinomas	89	7	0	0	0	0	0	0	0	0	10	0	0	0	0	0	1	0	11	0	1	0	0	
Carcinoma, unspecified	105	166	0	0	0	0	0	0	0	0	9	76	0	0	0	0	1	0	2	1	1	0	0	
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	0
Fibrosarcoma	11	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	12	0	0	0	0	0	3	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	18	0	0	0	0	0	1	0	6	0	0	0	0	0	1	0	0	0	0	0	0	5	0	0
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	9	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	6	0	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	20	1	0	0	0	0	1	0	17	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	19	0	9	0	0
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	4	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	12303	650	148	6	23	0	1	0	18	0	1363	0	112	0	1	0	298	8	23	1	10	1				
Small cell carcinoma	195	29	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0		
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Squamous cell carcinoma	1379	61	0	0	0	0	0	0	18	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Transitional cell carcinoma	333	5	1	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	22	1	9	0	0		
Adenocarcinoma	6223	215	140	4	20	0	0	0	0	0	1355	0	0	0	0	0	290	7	0	0	0	0	0	0		
Other specified carcinomas	89	7	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Carcinoma, unspecified	105	166	1	2	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	1	0		
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrosarcoma	11	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0		
Leiomyosarcoma	18	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant complex mixed and stromal tumors	78	0	2	0	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0		
Malignant fibroepithelial tumors	4	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0		
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	71	0	0	0	0	0	0	0	0	0	0		
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	32	0	0	0	0	0	0	0	0	0	0		
Malignant trophoblastic tumors	8	0	0	0	0	0	1	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0		
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12303	650	306	23	5	0	13	0	2	0	143	0	6	0	174	7	7	1	0	0	13	6
Small cell carcinoma	195	29	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1379	61	4	1	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	333	5	290	4	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6223	215	4	0	0	0	0	0	0	0	0	0	0	0	172	4	5	0	0	0	6	2
Other specified carcinomas	89	7	1	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	0	0	0	0
Carcinoma, unspecified	105	166	3	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	4
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Malignant melanoma	548	4	0	0	0	0	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	7	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	139	0	5	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	1	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	12303	650	26	1	32	14	10	1	65	26	56	1	107	3	226	11	26	2	19	3	1	0				
Small cell carcinoma	195	29	0	0	1	1	0	0	4	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Squamous cell carcinoma	1379	61	12	0	1	1	0	6	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Adenocarcinoma	6223	215	9	1	26	5	6	1	30	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified carcinomas	89	7	1	0	1	0	0	0	4	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Carcinoma, unspecified	105	166	3	0	2	6	2	0	7	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant melanoma	548	4	1	0	2	1	1	0	12	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	107	3	226	11	26	2	19	3	1	0				
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	56	1	0	0	0	0	0	0	0	0	0	0	0	0		
Plasma cell tumors	100	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic lymphoid leukemia	81	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leukemia except chronic lymphoid	134	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
	C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12303	650	100	10	107	22	99	15	5	1	29	0	3	1	141	32
Small cell carcinoma	195	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	58	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1379	61	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	1934	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	333	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6223	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified carcinomas	89	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	105	166	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	548	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	20	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	78	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	36	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	144	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	379	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	56	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	100	10	100	10	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	81	15	0	0	81	15	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	134	24	0	0	26	7	99	15	5	1	1	0	3	1	0	0
Other lymphoreticular neoplasms	3	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0
Chronic myeloproliferative diseases	103	7	0	0	0	0	0	0	0	0	28	0	0	0	75	7
Myelodysplastic syndromes	63	25	0	0	0	0	0	0	0	0	0	0	0	0	63	25
Other specified malignant tumors	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	11	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2014.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C00 – C80	Vse lokacije All sites	M+Ž	12708	6725	52,9	3358	26,4	2491	19,6	134	1,1
		M	6903	3612	52,3	1807	26,2	1402	20,3	82	1,2
C00	Ustnica Lip	M	22	21	95,5	1	4,5	0	0	0	0
		Ž	3	2	—	1	—	0	—	0	—
C01	Baza jezika Base of tongue	M	21	1	4,8	18	85,7	2	9,5	0	0
		Ž	2	2	—	0	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	19	4	21,1	15	78,9	0	0	0	0
		Ž	9	5	—	4	—	0	—	0	—
C03	Dlesen Gum	M	4	2	—	1	—	1	—	0	—
		Ž	4	2	—	2	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	32	9	28,1	23	71,9	0	0	0	0
		Ž	5	2	—	3	—	0	—	0	—
C05	Nebo Palate	M	15	6	40,0	8	53,3	1	6,7	0	0
		Ž	6	1	—	5	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	3	—	6	—	0	—	0	—
		Ž	6	3	—	3	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	11	2	—	8	—	1	—	0	—
		Ž	11	7	—	4	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	3	1	—	2	—	0	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C09	Tonzila Tonsil	M	43	10	23,3	30	69,8	3	7,0	0	0
		Ž	9	0	—	9	—	0	—	0	—
C10	Orofarinks Oropharynx	M	38	4	10,5	29	76,3	4	10,5	1	2,6
		Ž	4	0	—	3	—	1	—	0	—
C11	Nazofarinks Nasopharynx	M	6	1	—	4	—	1	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	26	1	3,8	23	88,5	2	7,7	0	0
		Ž	4	0	—	4	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	29	4	13,8	20	69,0	5	17,2	0	0
		Ž	7	0	—	7	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	—	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	100	16	16,0	44	44,0	31	31,0	9	9,0
		Ž	11	0	—	7	—	3	—	1	—
C16	Želodec Stomach	M	286	54	18,9	119	41,6	107	37,4	6	2,1
		Ž	166	34	20,5	60	36,1	66	39,8	6	3,6
C17	Tanko črevo Small intestine	M	27	8	29,6	10	37,0	9	33,3	0	0
		Ž	20	9	45,0	6	30,0	5	25,0	0	0
C18	Debelo črevo Colon	M	468	98	20,9	246	52,6	121	25,9	3	0,6
		Ž	341	66	19,4	203	59,5	70	20,5	2	0,6
C19	Rektosigmoidna zveza Rectosigmoid junction	M	87	23	26,4	45	51,7	19	21,8	0	0
		Ž	60	7	11,7	36	60,0	17	28,3	0	0
C20	Rektum Rectum	M	293	67	22,9	159	54,3	65	22,2	2	0,7
		Ž	152	35	23,0	88	57,9	29	19,1	0	0
C21	Anus in analni kanal Anus and anal canal	M	4	1	—	3	—	0	—	0	—
		Ž	13	4	—	7	—	2	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	141	57	40,4	40	28,4	37	26,2	7	5,0
		Ž	67	20	29,9	13	19,4	33	49,3	1	1,5
C23	Žolčnik Gallbladder	M	22	8	36,4	5	22,7	9	40,9	0	0
		Ž	46	12	26,1	12	26,1	22	47,8	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	74	17	23,0	35	47,3	19	25,7	3	4,1
		Ž	67	11	16,4	36	53,7	19	28,4	1	1,5
C25	Trebšna slinavka Pancreas	M	213	13	6,1	62	29,1	132	62,0	6	2,8
		Ž	179	20	11,2	75	41,9	81	45,3	3	1,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	—	0	—	2	—	0	—
		Ž	4	0	—	1	—	2	—	1	—

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	10	4	—	5	—	1	—	0	—
		Ž	8	4	—	4	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	9	0	—	9	—	0	—	0	—
		Ž	2	0	—	2	—	0	—	0	—
C32	Grlo Larynx	M	88	48	54,5	39	44,3	1	1,1	0	0
		Ž	9	3	—	6	—	0	—	0	—
C33	Sapnik Trachea	M	1	0	—	1	—	0	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	888	131	14,8	241	27,1	509	57,3	7	0,8
		Ž	430	89	20,7	99	23,0	241	56,0	1	0,2
C37	Timus Thymus	M	6	1	—	3	—	2	—	0	—
		Ž	2	0	—	0	—	2	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	3	1	—	1	—	1	—	0	—
		Ž	4	1	—	1	—	1	—	1	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	3	0	—	2	—	1	—	0	—
		Ž	4	2	—	2	—	0	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	11	4	—	6	—	1	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	281	211	75,1	66	23,5	4	1,4	0	0
		Ž	235	175	74,5	57	24,3	2	0,9	1	0,4
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1213	1198	98,8	15	1,2	0	0	0	0
		Ž	1220	1202	98,5	18	1,5	0	0	0	0
C45	Mezoteliom Mesothelioma	M	28	10	35,7	14	50,0	3	10,7	1	4
		Ž	9	4	—	5	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	5	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	1	—	0	—	1	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	2	0	—	1	—	1	—	0	—
		Ž	16	1	6	9	56,3	6	37,5	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	24	8	33,3	10	41,7	6	25,0	0	0
		Ž	28	5	17,9	12	42,9	10	35,7	1	0
C50	Dojka Breast	M	13	7	—	5	—	1	—	0	—
		Ž	1285	693	53,9	494	38,4	94	7,3	4	0,3
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	46	27	58,7	18	39,1	0	0	1	2,2
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	10	4	—	6	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	114	49	43,0	47	41,2	17	14,9	1	0,9
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	356	251	70,5	72	20,2	28	7,9	5	1,4
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	17	4	23,5	9	52,9	3	17,6	1	5,9
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	166	22	13,3	12	7,2	129	77,7	3	1,8
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	25	2	8,0	7	28,0	16	64,0	0	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	1	0	—	0	—	1	—	0	—
C60	Penis Penis	M	18	14	77,8	4	22,2	0	0	0	0
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1412	975	69,1	324	22,9	101	7,2	12	0,8
		Ž	—	—	—	—	—	—	—	—	—

Nadaljevanje →
Continued →

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
Localized		Regional		Distant		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C62	Modo Testis	M	112	89	79,5	9	8,0	14	12,5	0	0
		Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	0	—	1	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	214	132	61,7	34	15,9	46	21,5	2	0,9
		Ž	132	69	52,3	26	19,7	32	24,2	5	3,8
C65	Ledvični meh Renal pelvis	M	13	7	—	3	—	3	—	0	—
		Ž	13	5	—	4	—	3	—	1	—
C66	Sečevod Ureter	M	4	1	—	2	—	1	—	0	—
		Ž	7	1	—	4	—	2	—	0	—
C67	Sečni mehur Bladder	M	252	198	78,6	37	14,7	15	6,0	2	0,8
		Ž	82	54	65,9	13	15,9	12	14,6	3	3,7
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	5	2	—	2	—	1	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C69	Oklo in očesni adneksi Eye and adnexa	M	4	4	—	0	—	0	—	0	—
		Ž	9	5	—	4	—	0	—	0	—
C70	Meninge Meninges	M	1	1	—	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—	0	—
C71	Možgani Brain	M	98	98	100	0	0	0	0	0	0
		Ž	71	71	100	0	0	0	0	0	0
C72	Hrbtne mozeg, možganski živci in drugi deli ČS Spinal cord, cranial nerves and other parts of CNS	M	5	4	—	1	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	39	26	66,7	12	30,8	1	2,6	0	0
		Ž	142	119	83,8	19	13,4	4	2,8	0	0
C74	Nadledvična žleza Adrenal gland	M	3	1	—	1	—	1	—	0	—
		Ž	6	1	—	0	—	4	—	1	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	0	—	2	—	1	—	0	—
		Ž	25	0	0	7	28,0	17	68,0	1	4,0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	21	0	0	0	0	0	0	21	100
		Ž	7	0	—	0	—	0	—	7	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	42	0	0	0	0	42	100	0	0
		Ž	40	0	0	0	0	40	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	15	0	0	0	0	15	100	0	0
		Ž	7	0	—	0	—	7	—	0	—
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	58	0	0	0	0	58	100	0	0
		Ž	68	0	0	0	0	68	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage (Ann–Arbor)							
I		II		III+IV		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C81	Hodgkinova bolezen Hodgkin's disease	M	24	3	12,5	6	25,0	13	54,2	2	8,3
		Ž	33	0	0	8	24,2	24	72,7	1	3,0
C82– C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	215	41	19,1	15	7,0	134	62,3	25	11,6
		Ž	182	36	19,8	21	11,5	103	56,6	22	12,1

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2014.

Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2014.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vsi NHL All NHL	M+Ž	397	1	3	0	1	1	3	5	3	8	17	35	38	41	47	63	63	68
		M	215	1	2	0	1	1	2	3	0	5	11	17	23	23	29	36	34	27
		Ž	182	0	1	0	0	0	1	2	3	3	6	18	15	18	18	27	29	41
142	Slinavke Salivary glands	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
145	Usta, drugo Mouth, other parts	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
146	Orofarinks Oropharynx	M	7	0	0	0	0	0	0	0	0	0	2	1	1	1	0	1	1	
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	2	
151	Želodec Stomach	M	15	0	0	0	0	0	0	0	0	0	0	1	1	1	3	6	3	
		Ž	21	0	0	0	0	0	0	1	0	0	3	1	2	2	4	3	5	
152	Tanko črevo Small intestine	M	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
		Ž	4	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	
153	Debelo črevo Colon	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	
155	Jetra Liver	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	
170	Kosti Bone	M	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
173	Koža, drugi malignomi Skin, other malignancies	M	6	0	0	0	0	0	1	0	0	0	1	2	0	1	0	1	0	
		Ž	5	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	2	
174	Dojka Breast	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0		
184	Nožnica, vulva, drugo Vagina, vulva, etc.	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0		
185	Prostata Prostate	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
186	Modo Testis	M	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
190	Oko Eye	M	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	2	
		Ž	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	
191	Možgani Brain	M	8	0	0	0	0	0	0	0	0	0	0	3	1	2	1	1	0	
		Ž	6	0	0	0	0	0	0	0	1	0	0	1	1	0	2	1		
194	Ščitnica Thyroid	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1		
202	Bezgavke Lymph nodes	M	156	1	2	0	1	1	1	2	0	4	10	13	14	18	20	29	21	19
		Ž	122	0	1	0	0	0	1	1	2	2	4	12	13	9	14	19	18	26

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2014.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2014.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Vse vrste All types	M+Ž M Ž	694 374 320	33,7 36,6 30,8
9727, 9728, 9835, 9836, 9811–9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	M Ž	9 9	0,9 0,9
9727, 9835, 9836, 9811	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	M Ž	7 9	0,7 0,9
9812	Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities	M Ž	2 0	0,2 0,0
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	M Ž	4 0	0,4 0,0
9729, 9837	Limfoblastni limfom T / levkemija T T lymphoblastic lymphoma / leukaemia	M Ž	4 0	0,4 0,0
9591–9597, 9670–9699, 9712, 9731–9738, 9760–9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	M Ž	319 264	31,2 25,4
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	M Ž	72 43	7,0 4,1
9833	Levkemija s prolimfociti B B-cell prolymphocytic leukaemia	M Ž	1 0	0,1 0,0
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	M Ž	7 4	0,7 0,4
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	M Ž	7 13	0,7 1,2
9940	Dlakastocelična levkemija Hairy cell leukaemia	M Ž	6 3	0,6 0,3
9671	Limfoplazmatični limfom Lymphoplasmacytic lymphoma	M Ž	7 4	0,7 0,4
9761	Waldenströmova makroglobulinemija Waldenström macroglobulinemia	M Ž	0 1	0,0 0,1
9732, 9733	Multipli mielom Plasma cell myeloma	M Ž	53 53	5,2 5,1
9731, 9734	Solitarni kostni in zunajkostni plazmatom Solitary plasmacytoma of bone and extraosseous	M Ž	4 0	0,4 0,0
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	M Ž	11 16	1,1 1,5
9699, ektranodalni	B-celični limfom robne cone, ektranodalni Marginal zone B-cell lymphoma, extranodal	M Ž	14 22	1,4 2,1
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	M Ž	5 2	0,5 0,2
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	M Ž	13 15	1,3 1,4
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	M Ž	4 8	0,4 0,8
9673	Limfom plaščnih celic Mantle cell lymphoma	M Ž	22 4	2,2 0,4
9680, 9684	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	M Ž	89 69	8,7 6,6
9687, 9826	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	M Ž	1 3	0,1 0,3

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	M	2	0,2
		Ž	4	0,4
9596	Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasičnega Hodgkinovega limfoma B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL	M	1	0,1
		Ž	0	0,0
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	M	18	1,8
		Ž	13	1,2
9827, 9831, 9834, 9948	Levemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	M	0	0,0
		Ž	3	0,3
9831	Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	M	0	0,0
		Ž	1	0,1
9834	Prolimfocitna levkemija T T-cell prolymphocytic leukaemia	M	0	0,0
		Ž	1	0,1
9827	Limfom T odraslih / levkemija T odraslih Adult T-cell lymphoma / leukaemia	M	0	0,0
		Ž	1	0,1
9700, 9701, 9708, 9709, 9716–9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	M	5	0,5
		Ž	3	0,3
9700	Fungoidna mikoza Mycosis fungoides	M	3	0,3
		Ž	1	0,1
9701	Sézaryjev sindrom Sézary syndrome	M	1	0,1
		Ž	1	0,1
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	M	1	0,1
		Ž	1	0,1
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	M	13	1,3
		Ž	7	0,7
9702	Periferni limfom T (BDO- in ALK-negativni ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	M	8	0,8
		Ž	1	0,1
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M	3	0,3
		Ž	3	0,3
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	M	2	0,2
		Ž	3	0,3
9650–9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	M	24	2,3
		Ž	33	3,2
9659	HL z nodularno limfocitno predomnanco Nodular lymphocyte predominant HL	M	1	0,1
		Ž	0	0,0
9650	Klasični HL Classical HL	M	4	0,4
		Ž	3	0,3
9663, 9664, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	M	7	0,7
		Ž	23	2,2
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	M	10	1,0
		Ž	6	0,6
9653, 9654	Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL	M	2	0,2
		Ž	1	0,1
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukaemia	M	0	0,0
		Ž	1	0,1
9590	Maligni limfom, BDO Malignant lymphoma, NOS	M	0	0,0
		Ž	1	0,1

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so bili v okviru prvega kurativnega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by primary curative surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	13728	11109	80,9	8514	62,0	3994	29,1	3102	22,6
C00–C14	Usta in žrelo Mouth and pharynx	352	328	93,2	190	54,0	21	6,0	256	72,7
C15	Požiralnik Oesophagus	111	73	65,8	20	18,0	32	28,8	52	46,8
C16	Želodec Stomach	452	284	62,8	216	47,8	149	33,0	79	17,5
C18	Debelo črevo Colon	809	708	87,5	687	84,9	185	22,9	9	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	592	517	87,3	472	79,7	193	32,6	199	33,6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	208	64	30,8	31	14,9	33	15,9	3	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	209	86	41,1	79	37,8	12	–	3	–
C25	Trebušna slinavka Pancreas	392	140	35,7	76	19,4	87	22,2	13	–
C32	Grlo Larynx	97	92	94,8	50	51,5	2	–	70	72,2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1321	928	70,2	265	20,1	419	31,7	583	44,1
C43	Maligni melanom kože Malignant melanoma of skin	516	513	99,4	513	99,4	0	–	20	3,9
C44	Druge maligne neoplazme kože Skin, other malignomas	2433	2351	96,6	2220	91,2	14	0,6	131	5,4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	70	65	92,9	55	78,6	19	27,1	24	34,3
C50	Dojka Breast	1298	1249	96,2	1099	84,7	1140	87,8	766	59,0
C53	Maternični vrat Cervix uteri	114	105	92,1	81	71,1	5	–	60	52,6
C54	Maternično telo Corpus uteri	356	333	93,5	317	89,0	64	18,0	81	22,8
C56	Jajčnik Ovary	166	140	84,3	128	77,1	116	69,9	1	–
C61	Prostata Prostate	1412	1061	75,1	704	49,9	416	29,5	140	9,9
C62	Modo Testis	112	112	100	111	99,1	53	47,3	2	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	372	306	82,3	275	73,9	46	12,4	14	–
C67	Sečni mehur Bladder	334	296	88,6	290	86,8	36	10,8	24	7,2
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	178	150	84,3	135	75,8	80	44,9	127	71,3
C73	Ščitnica Thyroid gland	181	178	98,3	172	95,0	170	93,9	122	67,4
C81	Hodgkinova bolezen Hodgkin's disease	57	54	94,7	2	–	53	93,0	25	43,9
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	397	306	77,1	46	11,6	246	62,0	127	32,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	110	77	70,0	2	–	69	62,7	20	18,2
C91–C95	Levkemije Leukaemias	282	138	48,9	0	–	137	48,6	10	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so bili v okviru prvega kurativnega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by surgery during their first primary curative treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Brežice	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica dr. Jožeta Potrča Ptuj	Splošna bolnišnica Slovenj Gradec	Splošna bolnišnica Trbovlje	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13728	8514	30	632	124	249	158	2546	1242	1263	334	350	482	37	429	51	546	41
C00–C14	Usta in žrelo Mouth and pharynx	352	190	0	3	0	1	1	126	0	55	3	0	0	0	0	0	0	1
C15	Požiralnik Oesophagus	111	20	0	0	1	0	0	15	0	4	0	0	0	0	0	0	0	0
C16	Želodec Stomach	452	216	0	12	0	14	6	89	0	79	6	4	2	0	1	0	3	0
C18	Debelo črevo Colon	809	687	10	46	0	63	32	236	32	95	23	35	40	13	21	15	23	3
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	592	472	3	22	1	27	12	127	99	71	18	9	20	7	18	21	17	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	208	31	0	0	0	0	0	21	0	10	0	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	209	79	1	2	0	3	2	41	0	25	0	2	3	0	0	0	0	0
C25	Trebušna slinavka Pancreas	392	76	0	0	0	0	3	40	0	33	0	0	0	0	0	0	0	0
C32	Grlo Larynx	97	50	0	0	0	0	0	35	0	15	0	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1321	265	0	1	109	0	0	103	0	52	0	0	0	0	0	0	0	0
C43	Maligni melanom kože Malignant melanoma of skin	516	513	4	57	0	27	20	144	25	51	18	18	39	7	9	4	77	13
C44	Druge maligne neoplazme kože Skin, other malignomas	2433	2220	5	209	0	101	27	576	17	188	172	115	279	1	103	4	419	4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	70	55	1	3	0	0	1	8	28	7	1	2	2	0	1	0	1	0
C50	Dojka Breast	1298	1099	0	10	0	0	2	2	804	185	2	63	3	0	26	0	0	2
C53	Maternični vrat Cervix uteri	114	81	2	4	0	0	1	50	2	9	1	1	3	2	1	0	0	5
C54	Maternično telo Corpus uteri	356	317	0	37	0	6	11	117	41	55	17	10	4	4	9	2	0	4
C56	Jajčnik Ovary	166	128	1	7	0	1	7	47	25	19	2	4	5	1	3	3	0	3
C61	Prostata Prostate	1412	704	0	155	0	0	8	156	0	105	41	52	16	0	170	0	0	1
C62	Modo Testis	112	111	0	7	0	0	4	60	0	17	3	5	5	0	10	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	372	275	0	13	0	1	9	124	0	48	12	14	31	0	22	0	0	1
C67	Sečni mehur Bladder	334	290	0	22	0	0	6	139	0	54	10	9	19	0	30	0	0	1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	178	135	0	3	0	0	0	96	0	34	0	0	0	0	0	0	0	2
C73	Ščitnica Thyroid gland	181	172	0	7	8	0	0	38	113	6	0	0	0	0	0	0	0	0
C81	Hodgkinova bolezen Hodgkin's disease	57	2	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	397	46	0	2	1	1	2	22	7	7	1	1	0	0	0	0	2	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	110	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	282	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2014, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po lokacijah raka in bolnici posega.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2014, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13728	3994	88	120	20	438	2597	460	44	86	34	51	41	15
C00–C14	Usta in žrelo Mouth and pharynx	352	21	0	0	0	0	21	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	111	32	0	0	0	2	27	3	0	0	0	0	0	0
C16	Želodec Stomach	452	149	2	0	0	21	104	21	0	0	0	0	0	1
C18	Debelo črevo Colon	809	185	3	0	0	6	159	10	0	2	0	4	0	1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	592	193	2	0	0	1	183	5	0	1	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	208	33	1	0	0	19	4	8	0	0	0	0	0	1
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	209	12	0	0	0	6	3	3	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	392	87	1	0	0	28	36	20	0	1	0	1	0	0
C32	Grla Larynx	97	2	0	0	0	0	2	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1321	419	0	94	0	0	254	70	0	0	0	0	0	1
C43	Malignni melanom kože Malignant melanoma of skin	516	0	0	0	0	0	0	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2433	14	0	0	0	3	2	3	0	0	0	0	5	1
C48–C49	Veživo in mehko tkivo Connective and soft tissue	70	19	0	0	0	3	11	4	0	1	0	0	0	0
C50	Dojka Breast	1298	1140	17	2	4	1	863	194	0	46	0	11	0	2
C53	Maternični vrat Cervix uteri	114	5	0	0	0	0	5	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	356	64	0	0	0	0	43	20	1	0	0	0	0	0
C56	Jajčnik Ovary	166	116	0	0	0	0	91	24	0	1	0	0	0	0
C61	Prostata Prostate	1412	416	25	0	13	75	104	41	40	25	27	29	35	2
C62	Modo Testis	112	53	0	0	0	0	53	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	372	46	0	0	0	3	43	0	0	0	0	0	0	0
C67	Sečni mehur Bladder	334	36	0	0	0	1	28	0	0	0	2	5	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	178	80	0	0	0	2	77	0	0	0	0	0	0	1
C73	Ščitnica Thyroid gland	181	170	7	9	0	31	118	5	0	0	0	0	0	0
C81	Hodgkinova bolezen Hodgkin's disease	57	53	0	0	0	7	44	0	0	0	0	0	0	2
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	397	246	10	0	1	13	217	1	0	3	0	0	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	110	69	7	0	0	46	0	9	1	5	1	0	0	0
C91–C95	Levkemije Leukaemias	282	137	7	0	2	105	5	10	2	1	3	0	0	2

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2014.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2014.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	
C00	Vse lokacije	M+Ž	11094	32540	25798	34762	98331
C96	All sites	M	5887	16778	11988	12389	43905
		Ž	5207	15762	13810	22373	54426
C00–C14	Usta in žrelo Mouth and pharynx	M	226	559	363	445	1593
		Ž	69	184	174	232	659
C15	Požiralnik Oesophagus	M	56	47	15	23	141
		Ž	8	9	9	8	34
C16	Želodec Stomach	M	196	370	225	370	1161
		Ž	97	220	169	336	822
C18	Debelo črevo Colon	M	374	1317	791	854	3336
		Ž	286	947	728	969	2930
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	340	1059	697	732	2828
		Ž	174	565	520	703	1962
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	72	67	24	14	177
		Ž	25	22	7	9	63
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	53	43	29	24	149
		Ž	58	50	39	29	176
C25	Trebušna slinavka Pancreas	M	81	52	22	12	167
		Ž	83	55	28	16	182
C32	Grlo Larynx	M	83	247	211	330	871
		Ž	8	37	31	52	128
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	516	641	335	354	1846
		Ž	267	421	196	145	1029
C43	Malignni melanom kože Malignant melanoma of skin	M	275	851	634	696	2456
		Ž	229	874	857	1196	3156
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1190	4161	3113	3343	11807
		Ž	1200	4278	3481	4194	13153
C48–C49	Veživo in mehko tkivo Connective and soft tissue	M	25	71	71	173	340
		Ž	36	90	67	197	390
C50	Dojka Breast	M	11	39	20	33	103
		Ž	1240	4311	3994	6364	15909
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	102	383	505	2542	3532
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	331	1024	963	2150	4468
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	137	362	276	844	1619
C61	Prostata Prostate	M	1322	4885	3423	1504	11134
		Ž	–	–	–	–	–
C62	Modo Testis	M	111	400	452	1246	2209
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehcom Kidney with renal pelvis	M	192	633	498	503	1826
		Ž	112	309	264	393	1078
C67	Sečni mehur Bladder	M	211	513	333	361	1418
		Ž	63	150	112	143	468
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	80	89	69	187	425
		Ž	52	71	60	136	319
C73	Ščitnica Thyroid gland	M	35	147	115	192	489
		Ž	141	408	537	777	1863
C81	Hodgkinova bolezen Hodgkin's disease	M	22	78	101	327	528
		Ž	32	82	80	308	502
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	171	446	303	455	1375
		Ž	151	453	365	470	1439
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	45	138	72	32	287
		Ž	43	132	66	31	272
C91–C95	Levkemije Leukaemias	M	124	298	226	325	973
		Ž	84	222	172	304	782

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2014.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00 – C97	Vse lokacije All sites	M+Ž	5898	0	4	1	2	4	4	14	30	58	109	235	424	662	619	854	908	1970
		M	3310	0	2	1	1	0	1	8	14	26	54	138	260	424	389	533	524	935
		Ž	2588	0	2	0	1	4	3	6	16	32	55	97	164	238	230	321	384	1035
C00	Ustnica Lip	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C01	Baza jezika Base of tongue	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	12	0	0	0	0	0	0	0	0	0	2	0	5	1	2	2	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C03	Dlesen Gum	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C04	Ustno dno Floor of mouth	M	5	0	0	0	0	0	0	0	0	0	0	3	0	0	0	1	1	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C05	Nebo Palate	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	14	0	0	0	0	0	0	0	0	1	1	0	0	6	2	2	1	1
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C07	Parotidna žleza Parotid gland	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C09	Tonzila Tonsil	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Orofarinks Oropharynx	M	53	0	0	0	0	0	0	0	0	0	4	6	8	14	6	5	6	4
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1
C11	Nazofarinks Nasopharynx	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	30	0	0	0	0	0	0	0	1	0	2	4	7	10	0	4	2	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	8	0	0	0	0	0	0	0	0	1	1	0	3	1	2	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C15	Požiralnik Oesophagus	M	74	0	0	0	0	0	0	0	0	0	5	5	18	13	10	10	5	8
		Ž	12	0	0	0	0	0	0	0	0	1	2	0	1	2	1	2	1	2
C16	Želodec Stomach	M	214	0	0	0	0	0	0	2	2	1	4	7	12	16	11	46	37	76
		Ž	145	0	0	0	0	1	0	1	1	1	1	5	11	2	10	16	17	79
C17	Tanko črevo Small intestine	M	9	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5
		Ž	5	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
C18	Debelo črevo Colon	M	250	0	0	0	0	0	0	1	0	3	3	7	7	26	32	43	40	88
		Ž	184	0	0	0	0	0	0	0	0	3	2	5	10	12	12	26	28	86
C19	Rektosigmoidna zveza Rectosigmoid junction	M	32	0	0	0	0	0	0	0	0	1	0	3	4	4	4	5	6	5
		Ž	31	0	0	0	0	0	0	0	0	0	0	2	0	5	2	2	2	18
C20	Rektum Rectum	M	138	0	0	0	0	0	0	0	0	1	3	10	7	17	17	30	23	30
		Ž	103	0	0	0	0	0	0	0	0	1	4	1	4	9	4	17	14	49
C21	Anus in analni kanal Anus and anal canal	M	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	146	0	0	0	0	0	0	0	0	1	2	5	13	26	24	25	23	27
		Ž	88	0	0	0	0	0	0	0	0	0	2	2	4	3	8	8	20	41
C23	Žolčnik Gallbladder	M	18	0	0	0	0	0	0	0	0	1	0	0	1	1	1	6	3	5
		Ž	40	0	0	0	0	0	0	0	0	2	1	0	2	2	4	2	7	20
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	42	0	0	0	0	0	0	0	0	0	0	0	2	2	5	11	12	10
		Ž	38	0	0	0	0	0	0	0	0	0	0	1	2	1	3	5	7	19
C25	Trebušna slinavka Pancreas	M	213	0	0	0	0	0	0	2	2	2	14	16	38	30	35	38	36	0
		Ž	162	0	0	0	0	0	0	1	0	1	6	9	12	14	26	29	63	0
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	6
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	2	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C32	Grlo Larynx	M	41	0	0	0	0	0	0	0	0	0	0	3	4	6	2	11	4	11
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	4	1	0	0	0
C33	Sapnik Trachea	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C34	Sapnica in pljuča Bronchus and lung	M	786	0	0	0	0	0	0	0	0	0	4	12	37	90	136	130	131	114	132
		Ž	392	0	0	0	0	0	0	0	0	1	6	6	16	48	61	51	52	61	90
C37	Timus Thymus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	3
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	4
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1
		Ž	7	0	0	0	0	1	1	0	0	0	1	0	0	1	1	1	0	0	2
C43	Maligni melanom kože Malignant melanoma of skin	M	63	0	0	0	0	0	0	1	4	3	1	4	5	6	9	8	8	8	14
		Ž	48	0	0	0	0	0	0	0	0	1	3	3	4	4	5	7	5	5	16
C44	Druge maligne neoplazme kože Skin, other malignomas	M	10	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	3	5	
		Ž	13	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	12
C45	Mezoteliom Mesothelioma	M	30	0	0	0	0	0	0	0	0	1	0	1	0	4	4	4	9	7	
		Ž	10	0	0	0	0	0	0	0	0	0	2	1	0	1	1	2	1	2	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1
		Ž	16	0	0	0	0	0	0	0	0	0	1	0	1	1	1	5	3	4	4
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	10	0	0	0	0	0	0	0	0	0	0	2	0	2	2	2	2	2	
		Ž	18	0	0	0	0	1	0	0	0	0	1	0	2	4	3	0	7	7	
C50	Dojka Breast	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	
		Ž	379	0	0	0	0	0	0	1	9	10	12	18	22	30	31	50	48	148	
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	21	0	0	0	0	0	0	0	0	1	0	1	1	2	2	5	9	9	
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	2	
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	49	0	0	0	1	0	0	1	2	3	9	0	6	7	6	4	10	10	
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	63	0	0	0	0	0	0	0	0	1	3	4	8	8	7	8	24	24	
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	43	0	0	0	0	0	0	0	0	1	1	4	5	3	7	4	18	18	
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	140	0	0	0	0	0	1	1	1	4	6	14	14	11	25	16	47	47	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	1	
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C60	Penis Penis	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C61	Prostata Prostate	M	372	0	0	0	0	0	0	0	0	0	0	2	8	16	21	38	61	226	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C62	Modo Testis	M	6	0	0	0	0	0	1	1	2	1	0	0	0	0	0	1	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
C64	Ledvica razen meha Kidney, except renal pelvis	M	89	0	0	0	0	0	0	0	0	1	3	3	10	6	8	23	15	20	
		Ž	61	0	0	0	0	0	0	0	0	0	0	1	2	4	5	4	15	30	
C65	Ledvični meh Renal pelvis	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	0	1	3	1	1	
C66	Sečevod Ureter	M	5	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	2	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	
C67	Sečni mehur Bladder	M	124	0	0	0	0	0	0	0	0	1	1	2	3	12	9	13	22	61	
		Ž	53	0	0	0	0	0	0	0	0	1	0	1	2	3	5	4	13	24	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C69	Oko in očesni adneksi Eye and adnexa	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	
		Ž	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+		
C70	Meninge Meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	1	3	
C71	Možgani Brain	M	67	0	0	0	1	0	0	1	2	1	4	4	13	12	6	9	8	6		
		Ž	59	0	1	0	1	0	0	0	2	1	2	2	7	9	6	6	11	11		
C72	Hrbtni mozeg, možganski žvci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C73	Ščitnica Thyroid gland	M	7	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	4		
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1		
C74	Nadledvična žleza Adrenal gland	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2		
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C76	Druge in slabo opredeljena mesta Other and ill-defined sites	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2		
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	10	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	6		
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	5			
C79	Metastaze, drugje Metastases of other sites	M	6	0	0	0	0	0	0	0	0	0	0	2	0	0	2	1	1	1		
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	2			
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	38	0	0	0	0	0	0	0	0	1	3	2	6	4	7	3	12			
		Ž	45	0	0	0	0	0	0	1	0	0	0	0	4	2	5	11	22			
C81	Hodgkinova bolezen Hodgkin's disease	M	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2		
		Ž	8	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	5			
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	2			
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	3			
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	34	0	0	1	0	0	0	0	1	0	2	2	4	5	7	5	7			
		Ž	33	0	0	0	0	0	0	1	1	1	0	0	4	0	2	4	20			
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	8	0	0	0	0	0	0	0	0	1	1	0	0	3	0	2	1			
		Ž	5	0	0	0	0	0	0	0	0	1	0	1	0	2	0	1	0			
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	52	0	0	0	0	0	0	0	0	0	5	2	2	7	13	9	14			
		Ž	39	0	0	0	0	0	0	0	0	0	0	0	2	1	2	8	26			
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	43	0	0	0	0	0	0	0	0	0	1	3	8	6	4	9	12			
		Ž	54	0	0	0	0	0	0	0	0	0	1	2	0	3	6	7	13	22		
C91	Limfatična levkemija Lymphoid leukaemia	M	48	0	1	0	0	0	0	2	0	0	0	2	1	6	5	4	8	19		
		Ž	32	0	0	0	0	0	0	0	0	0	0	1	0	3	2	3	4	19		
C92	Mieločna levkemija Myeloid leukaemia	M	51	0	0	0	0	0	0	0	0	0	0	1	3	3	8	7	10	19		
		Ž	37	0	0	0	1	0	0	0	0	0	2	1	2	6	4	3	4	14		
C93	Monocitna levkemija Monocytic leukaemia	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0		
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0		
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	6	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	4			
		Ž	7	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	6			
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva Other & unspecified malignant neoplasms of lymphoid, haemopoetic & related tissues	M	22	0	1	0	0	0	0	0	0	1	0	0	2	1	2	3	12			
		Ž	23	0	0	0	0	0	0	0	0	0	1	0	1	0	1	3	17			
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independent (primary) multiple sites	M	62	0	0	0	0	0	0	0	0	0	1	1	2	8	3	12	14	22		
		Ž	22	0	0	0	0	0	0	0	0	0	1	0	3	2	4	4	2	6		
Zgoraj neupoštevani Not included above																						
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0		
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	1	0	0	3	3	4		
D33	ČŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1			
D43	ČŽS, neopredeljeno CNS, uncertain or unknown	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		

Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja, IZ) bolnikov, zbolelih za izbranimi raki v letih 2010–2014 po spolu.

Table 14: One-, three- and five-year net survival (with 95% confidence interval, CI) of patients diagnosed with selected cancers in period 2010–2014 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje; 95 % IZ		Tro-letno preživetje; 95 % IZ		Pet-letno preživetje; 95 % IZ	
			One-year survival; 95% CI		Three-year survival; 95% CI		Five-year survival; 95% CI	
C00–C96**	Vse lokacije All sites	M+Ž	78,0	77,7–78,4	68,4	68,0–68,8	65,0	64,5–65,5
		M	76,4	75,9–76,9	66,1	65,5–66,7	62,6	62,0–63,4
		Ž	80,0	79,5–80,4	71,1	70,6–71,7	67,7	67,0–68,5
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	73,1	72,8–73,5	61,2	60,8–61,7	56,8	56,2–57,3
		M	71,7	71,1–72,2	59,3	58,7–59,9	55,0	54,2–55,7
		Ž	75,0	74,4–75,6	63,6	63,0–64,3	59,0	58,2–59,8
C00–C14	Usta in žrelo Mouth and pharynx	M	72,9	70,5–75,4	51,2	48,4–54,1	43,2	40,0–46,5
		Ž	81,3	77,1–85,7	67,7	62,5–73,4	61,2	54,4–68,9
C15	Požiralnik Oesophagus	M	38,7	34,0–44,2	12,9	9,7–17,1	8,7	5,8–13,0
		Ž	*		*		*	
C16	Želodec Stomach	M	50,8	48,2–53,6	33,0	30,4–35,7	28,9	26,2–31,9
		Ž	46,5	43,2–50,0	31,1	28,0–34,6	29,2	26,0–32,9
C18	Debelo črevo Colon	M	80,5	78,9–82,2	68,3	66,2–70,5	63,5	61,0–66,2
		Ž	76,2	74,2–78,3	65,3	62,8–67,8	60,9	58,0–63,9
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	84,2	82,4–85,9	70,4	68,0–72,8	63,7	60,9–66,7
		Ž	79,2	76,6–81,7	66,2	63,1–69,4	59,5	55,9–63,3
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	30,9	27,4–34,7	13,9	11,3–17,0	7,9	5,6–11,0
		Ž	26,9	21,8–33,3	9,8	6,6–14,6	3,3	1,5–7,5
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	35,1	30,4–40,5	17,4	13,7–22,1	13,2	9,5–18,2
		Ž	27,5	23,8–31,8	13,5	10,7–17,1	10,8	7,9–14,7
C25	Trebšna slinavka Pancreas	M	20,9	18,3–23,8	6,8	5,3–8,8	5,3	3,8–7,3
		Ž	22,3	19,7–25,4	6,9	5,3–8,9	4,7	3,3–6,7
C32	Grlo Larynx	M	86,6	83,3–90,1	72,1	67,5–76,9	66,0	60,6–71,9
		Ž	*		*		*	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	38,7	37,2–40,2	18,3	17,1–19,5	13,8	12,6–15,1
		Ž	48,4	46,2–50,7	26,1	24,2–28,2	20,0	18,0–22,1
C43	Maligni melanom kože Malignant melanoma of skin	M	97,0	95,7–98,3	90,4	88,1–92,7	86,5	83,3–89,7
		Ž	97,3	96,0–98,5	91,2	89,0–93,4	89,4	86,6–92,4
C44	Druge maligne neoplazme kože Skin, other malignomas	M	**		**		**	
		Ž	**		**		**	
C48–C49	Veživo in mehko tkivo Connective and soft tissue	M	80,3	73,5–87,7	65,0	56,6–74,6	64,5	54,5–76,3
		Ž	75,6	69,6–82,0	58,5	51,6–66,3	45,0	37,1–54,5
C50	Dojka Breast	M	*		*		*	
		Ž	96,4	95,8–97,0	90,9	89,9–91,8	86,5	85,2–87,9
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–
		Ž	85,7	83,0–88,6	72,7	69,2–76,5	70,0	66,0–74,1
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–
		Ž	92,5	91,1–94	83,7	81,6–85,9	79,8	77,1–82,5
C56	Jajčnik Ovary	M	–	–	–	–	–	–
		Ž	77,0	74,0–80,0	54,3	50,8–58,0	41,7	38,0–45,7
C61	Prostata Prostate	M	96,5	95,9–97,1	92,4	91,4–93,4	90,1	88,7–91,5
		Ž	–	–	–	–	–	–
C62	Modo Testis	M	98,3	97,1–99,5	98,4	97,0–99,8	98,2	96,2–100,0
		Ž	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	80,1	77,7–82,6	71,1	68,2–74,2	67,3	63,8–70,9
		Ž	76,5	73,0–80,1	66,8	62,8–71,1	65,5	61,0–70,4
C67	Sečni mehur Bladder	M	76,1	73,4–78,9	63,4	60,1–66,9	56,1	51,9–60,5
		Ž	67,8	63,0–72,9	52,2	46,8–58,1	43,4	37,1–50,8
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	51,7	47,1–56,7	25,1	21,2–29,7	20,4	16,6–25,0
		Ž	42,8	37,9–48,4	23,6	19,5–28,5	20,8	16,8–25,8
C73	Ščitnica Thyroid gland	M	93,2	89,4–97,1	90,0	85,0–95,3	88,6	82,4–95,2
		Ž	97,4	96,0–98,9	96,5	94,5–98,5	95,6	93,0–98,4
C81	Hodgkinova bolezen Hodgkin's disease	M	94,3	89,8–99,0	89,9	83,9–96,4	88,4	81,4–95,9
		Ž	91,6	86,8–96,7	89,5	83,7–95,6	88,4	81,1–96,2
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	78,5	75,6–81,4	68,8	65,3–72,4	65,5	61,3–70,0
		Ž	78,3	75,4–81,3	68,0	64,6–71,7	63,3	59,3–67,5
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	69,9	64,8–75,4	52,6	46,8–59,1	42,0	35,8–49,4
		Ž	70,3	65,2–75,8	52,6	46,9–59,0	39,3	32,6–47,2
C91–C95	Levkemije Leukaemias	M	64,0	60,6–67,6	53,5	49,7–57,6	45,5	41,2–50,2
		Ž	62,3	58,3–66,5	54,1	49,7–58,8	47,4	42,4–53,0

* Število v analizo vključenih bolnikov je povprečno letno manjše od 15

* Annual average number of patients included in the analysis is less than 15

** Preživetje bolnikov z nemelanomskim kožnim rakom je primerljivo preživetju v splošni populaciji

** Survival of patients with non-melanoma skin cancer is comparable to the general population

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2012

- Čuić M, Zadnik V. Prekomerna telesna teža in debelost kot dejavnik tveganja raka = Overweight and obesity as cancer risk factor. In: Babnik K, Kocbek M, eds. Slovenski dan dietetike: prva znanstvena konferenca z mednarodno udeležbo, Izola, 25. oktober 2012. Zbornik prispevkov. Koper: Založba Univerze na Primorskem, 2012: 63–8.
- Glumac N, Hočevnar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. *Radiol Oncol* 2012; 46(3): 258–64.
- Gregorič B, Zadnik V, Jezeršek Novaković B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. *Radiol Oncol* 2012; 46(2): 153–9.
- Ivanuš U, Primic-Žakelj M. Interlaboratory variability in HPV-positive rates in ASC-US/LSIL smears in the cervical cancer screening programme ZORA = Razlike med citološkimi laboratoriji v deležu HPV-pozitivnih izvidov APC-N/PIL-NS v presejalnem programu za raka materničnega vratu ZORA. In: Strojčan Fležar M, Luzar B, Gutnik H, Pižem J, Kocjan G, eds. Novosti v citopatologiji: most med kliniko in diagnostično patologijo: Bridge between clinics and diagnostic pathology. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2012: 203–8.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 53–63.
- Ivanuš U, Primic-Žakelj M. Samoodvzem vaginalnega vzorca za test HPV pri neodzivnicah presejalnih programov raka materničnega vratu. *Onkologija* 2012; 16(2): 78–86.
- Ivanuš U, Primic-Žakelj M. Tretji izobraževalni dan programa ZORA. *Onkologija* 2012; 16(2): 98–100.
- Jarm K. Podrobna raziskava preživetja bolnikov z rakom danke v Sloveniji, zbolelih v letih 2003–2005: specialistična naloga s področja javnega zdravja. Ljubljana: Onkološki inštitut; 2012.
- Koivisto-Korander R, Scélo G, Ferro G, Mellekjaer L, Hemminki K, Pompe-Kirn V, et al. Second primary malignancies among women with uterine sarcoma. *Gynecol Oncol* 2012; 126(1): 30–5.
- Kovač V, Zwitter M, Žagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. *Radiol Oncol* 2012; 46(2): 136–44.
- Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Primic-Žakelj M, et al. Breast cancer incidence trends in European women aged 20-39 years at diagnosis. *Breast Cancer Res Treat* 2012; 134(1): 363–70.
- Primic-Žakelj M, Ivanuš U. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 9–14.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Rak pri starostniku. Ljubljana: Onkološki inštitut, 2012: 14–25.
- Primic-Žakelj M, Žagar T. Razširjenost, preprečevanje in zgodnje odkrivanje pljučnega raka. In: Matković M, ed. Pacienti in pljučni rak - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2012: 19–31.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. *Slov 2000 Rak* 2012: 6–9.
- Primic-Žakelj M. Razširjenost in pomen redkih rakavih bolezni. In: Primic-Žakelj M, ed. Redki raki. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–13.

- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Fležar MS. Review of negative and low-grade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathol Off J Br Soc Clin Cytol* 2012; 23(1): 23–9.
- Uršič-Vrščaj M, Ivanuš U. HPV testiranje. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj, Ljubljana, marec 2012. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2012: 63–9.
- Zadnik V, Primic-Žakelj M. Epidemiologic data on cervical cancer. In: Takač I, ed. Recent advances in cervical cancer. Kerala: Transworld Research Network, 2012: 1–7.
- Zadnik V, Primic-Žakelj M, Krajc M. Breme raka v Sloveniji v primerjavi z drugimi evropskimi državami = Cancer burden in Slovenia in comparison with the burden in other European countries. *Zdr Vestn* 2012; 81(5): 407–12.
- Zadnik V, Žagar T, Primic-Žakelj M. Analiza vpliva točkovnih virov onesnaženja na zbolevanje za rakom v Zasavju = Analysis of the impact of point source pollution on cancer in Zasavje. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1.
- Žagar T, Florjančič M, Ivanuš U, Krajc M, Šval C, Zadnik V, et al. Register raka in presejalna programa ZORA in DORA - povezovanje z drugimi državnimi podatkovnimi zbirkami ter projekt eZdravje = Cancer registry and screening programs ZORA and DORA - connection to other state databases and eHealth project. In: Orel M, Jurjevčič S, eds. Mednarodna konferenca InfoKomTeh 2012, Ljubljana, 25. oktober 2012 = International Conference InfoKomTeh 2012, 25th October 2012. Polhov Gradec: Eduvision, 2012: 94–104.
- Žagar T, Primic-Žakelj M, Zadnik V. Slovenian maps of local standardized incidence ratio. In: 34th International Association of Cancer Registries Conference, 17–19 September 2012. Cork: The National Cancer Registry, 2012: 42.
- Žagar T, Zadnik V, Primic-Žakelj M. Možnosti raziskovanja vpliva bivalnega okolja na pojavljanje raka. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1–15.
- Žist A, Milanez T, Škrbinc B, Zadnik V, Šeruga B. Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja. *Onkologija* 2012; 16(2): 74–7.

2013

- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Primic-Žakelj M, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. *International journal of cancer* 2013; 132: 1170–81.
- Gašljevič G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gašparov S. HER2 in gastric cancer: and immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental FISH study. *Pathol Oncol Res* 2013; 19: 855–65.
- Ivanuš U, Primic-Žakelj M, Žagar T, Florjančič M, Kuster M. Delovanje državnega presejalnega programa za raka materničnega vratu ZORA v osrednjeslovenski statistični regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 74–94.
- Ivanuš U, Primic-Žakelj M. Klinična uporaba in pomen testa za humani papilomski virus v Državnem presejalnem programu ZORA (Clinical use and value of human papillomavirus test in national cervical cancer screening programme ZORA). *Med Razgl* 2013; 52(3): 123–35.
- Ivanuš U, Primic-Žakelj M. Pomen izvida testa HPV v kolposkopski ambulanti. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2013: 78–101.
- Ivanuš U, Primic-Žakelj M. Uporaba triaznega testa HPV v programu ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 27–34.
- von Karsa L, Maučec-Zakotnik J, Primic-Žakelj M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013; 45, 51–9.

- Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Radiol Oncol* 2013; 47: 161–5.
- Krajc M, Šval C, Kadivec M, Hertl K, Primic-Žakelj M. Rezultati državnega presejalnega programa Dora v ljubljanski regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 66–73.
- Maver Vodičar P, Seme K, Korač T, Dimitrov G, Döbrössy L, Primic-Žakelj M, et al. Cervical cancer screening practices in central and eastern Europe in 2012. *Acta Dermatovenerol APA* 2013; 22: 7–19.
- Primic-Žakelj M, Ivanuš U. Deset let delovanja programa ZORA. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 7–11.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke. In: Šola tumorjev prebavil, Ljubljana, 30. 11. 2012. Ljubljana: Onkološki inštitut, 2013: 17–20.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka prostate, sečnega mehurja, ledvic in mod v Sloveniji. In: Novaković S, ed. Izzivi v multidisciplinarni obravnavi bolnikov z rakom sečnega mehurja, prostate, ledvic in mod. Zbornik. Ljubljana: Onkološki inštitut: Kancerološko združenje Slovenskega zdravniškega društva, 2013: 16–23.
- Primic-Žakelj M. Epidemiology of cancer diseases in different European regions and the importance of risk factors. In: Fourth International Medical Congress, 11-15 September 2013, Portorož, Slovenia, 2013: 49–51.
- Primic-Žakelj M, Ivanuš U, Žagar T. Neodzivnice DP DORA so bolj ogrožene z rakom materničnega vratu (Non-responders to the National Cervical Cancer Screening Programme Zora are at an increased risk of cervical cancer). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 29.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak dojke: zbolewnost, preživetje in dejavniki tveganja. In: Matković M, ed. Pacientke z rakom dojk - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2013: 5–13.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. In: Novosti v diagnostiki in zdravljenju raka, Ljubljana, 13. decembra 2013: ob jubilejni, 20. obletnici delovanja združenja Fundacija doc. dr. Josip Cholewa v sodelovanju z Medicinsko fakulteto Ljubljana, Kliničnim centrom Ljubljana in Onkološkim inštitutom Ljubljana. Ljubljana: Fundacija doc. dr. Josip Cholewa, 2013: 5–6.
- Zadnik V, Žagar T, Jarm K, Primic-Žakelj M. The evaluation of the mesothelioma epidemic in Slovenia. In: 35th International Association of Cancer Registries Conference, 22-24 October 2013, Buenos Aires. Programme & abstracts. Buenos Aires: The National Cancer Institute, 2013: 109.
- Zadnik V, Ivanuš U, Žagar T, Primic-Žakelj M. Pojavljanje raka na območju upravnih enot Celje in Šentjur pri Celju (Cancer incidence in administrative units Celje and Šentjur pri Celju). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 74.
- Znaor A, van den Hurk C, Primic-Žakelj M, Agius D, Coza D, Demetriou A, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade : gaps persist compared with the rest of Europe. *Eur J Cancer* 2013; 49: 1683–91.
- Žagar T, Zadnik V, Primic-Žakelj M. Local estimation of standardized incidence ratio applied to Slovenian cancer data. V: International Conference Applied Statistics 2013, September 22-25, 2013, Ribno (Bled), Slovenia. Lusa L, Stare J, eds. Abstracts and program. Ljubljana: Statistical Society of Slovenia, 2013: 55.
- Žagar T, Primic-Žakelj M, Zadnik V. Zemljevidi raka, narejeni z metodo lokalno ocenjenega standardiziranega količnika (Cancer maps created with local standardized incidence ratio method). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 71.

2014

- Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. *J Eur Acad Dermatol Venereol* 2014; 28: 1170–8.
- Gutnik H, Matič JP, Primic-Žakelj M, Strojan Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001–2007. *Radiol Oncol* 2014; 48: 282–8.
- Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45–52.
- Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48–69.
- Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B, eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99–106.
- Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J, ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221–8.
- Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64–72.
- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešič N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. *Clinical genetics* 2014; 85: 59–63.
- Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novaković S, Ivanuš U, Primic-Žakelj M, et al. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36–40.
- Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6–7.
- Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A, eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249–55.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7–11.
- Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27–36.
- Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanec A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1–4.
- Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J, ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115–24.

- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7–34.
- Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: European Union and European Network of Cancer Registries (ENCR). Towards a harmonised cancer information system in Europe, 2014: 71.
- Strojan P, Zadnik V, Šifer R, Lanišnik B, Didanovič V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. *Eur Arch Otorhinolaryngol* 2014: 1–7.
- Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. *Cancer investigation* 2014; 32: 99–104.
- Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67–73.
- Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J, ed. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacolom Slovenija, združenje za boj proti raku debelega črevesa in danke, 2014: 22–4.
- Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Gajšek P, ed. Strokovni seminar Daljnovodi in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirana sevanja, 2014: 19–21.
- Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M, et al. Economic evaluation of cancer registration in Europe. *J Registry Manag* 2014; 41: 31–7.
- Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), 36th annual conference 2014. Ottawa, Canada, 26-28 June 2014. Ottawa: The National Cancer Institute, 2014: 109.

2015

- Allemani C, Weir HK, Carreira H, Harewood R, Primic-Žakelj M, Žagar T, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015; 385: 977–1010.
- Borrás JM, Barton M, Grau C, Corral J, Verhoeven R, Primic-Žakelj M, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. *Radiother Oncol* 2015; 116: 45–50.
- Borrás JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Primic-Žakelj M, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. *Radiother Oncol* 2015; 116: 38–44.
- Ivanuš U, Primic-Žakelj M. Test HPV doma za neodzivnice programa Zora: preliminarni rezultati. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana; 2015: 49–55.
- Ivanuš U, Primic-Žakelj M. Vloga triaznega testa HPV in kolposkopije v programu ZORA. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD in Onkološki inštitut, 2015: 35–52.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki in preprečevanje s cepljenjem. In: Novaković S, Zakotnik B, Žgajnar J, eds. Preprečevanje raka: dejstva, ki jih mora vedeti zdravstveni delavec: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2015: 89–102.
- Jarm K, Krajc M, Primic-Žakelj M, Šval C, Purić F, Kadivec M, et al. Presejanje za raka dojke: program Dora. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 70–5.

- Karalexi MA, Papathoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983-2014): Gaps persist across 14 cancer registries. *Eur J Cancer* 2015; 51: 2665-77.
- Krajc M, Primic-Žakelj M. Dojenje, hormonska zdravila in drugi dejavniki, vpleteni v nastanek raka dojk. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 77-86.
- Papathoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. *Eur J Cancer* 2015; 51: 1444-55.
- Primic-Žakelj M. Redke rakave bolezni. In: Modic K, ed. Redke bolezni: 28 februar 2015. Ljubljana: Društvo BKB, 2015: 35-40.
- Primic-Žakelj M. Kaj je evropski kodeks proti raku. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 7-9.
- Primic-Žakelj M, Čeh F. Najpogostejši raki pri moških 2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Čeh F. 12 nasvetov proti raku : Evropski kodeks proti raku 2014-2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP Zora - 2014/2015. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 7-10.
- Primic-Žakelj M, Žagar T. Preprečevanje raka v ustni votlini. In: Artnik B, Premik M, Jovanovič K, eds. Zbornik člankov in izvlečkov, Kongres ob 40-letnici strokovnih srečanj stomatologov Slovenije [tudi] 40 srečanje stomatologov Slovenije "Iz prakse za prakso" in pridruženi 10 Cvahtetovi dnevi javnega zdravja "Skrb za ustno zdravje", Portorož, 4 do 6 junij 2015. Ljubljana: Stomatološka sekcija Slovenskega zdravniškega društva, 2015: 22-9.
- Rems M, Jarm K, Zadnik V, Primic-Žakelj M. Lokalna ponovitev bolezni pri bolnikih, operiranih zaradi nemetastatskega raka danke, zbolelih v obdobju 2003-2005 = Local recurrence of rectal cancer in patients with nonmetastatic disease, diagnosed in 2003-2005. *Zdrav vest* 2015; 84: 277-86.
- Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Hollecsek B, Primic-Žakelj M, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. *Eur J Cancer* 2015; 51: 2191-205.
- Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, Primic-Žakelj M, et al. Cancer survival in Europe, 2000-2007: Doing better, feeling worse? *Eur J Cancer* 2015; 51: 2101-3.
- Schuz J, Espina C, Villain P, Herrero R, Leon ME, Primic-Žakelj M, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. *Cancer epidemiol* 2015; 39 Suppl 1: S1-10.
- Strojjan P, Zadnik V, Sifrer R, Lanisnik B, Didanovic V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983-2009: role of human papillomavirus infection. *Eur Arch Otorhinolaryngol* 2015; 272: 3805-14.
- Zadnik V. Epidemiologija raka jajčnika. In: Smrkolj S, Zobec Logar H, Šešek M, eds. Rak jajčnikov: zbornik. Ljubljana: Slovensko zdravniško društvo, Združenje za radioterapijo in onkologijo, 2015: 6-9.
- Zadnik V. Epidemiološki trendi hormonsko odvisnih rakov = Epidemiological trends of hormon related cancers. In: Černe K, ed. Kemijski povzročitelji hormonskih motenj od molekule do človeka = Endocrine disrupting chemicals - from molecule to man. Ljubljana: Slovensko toksikološko društvo, 2015: 22.
- Zanetti R, Schmidtman I, Sacchetto L, Binder-Foucard F, Bordoni A, Zadnik V, et al. Completeness and timeliness: Cancer registries could/should improve their performance. *European journal of cancer*. 2015; 51: 1091-8.
- Zwitter M, Žagar T. Zdravljenje pljučnega raka: perspektiva dveh desetletij. In: Kovač V, Rajer M, eds. Prva šola pljučnega raka. Ljubljana: Slovensko zdravniško društvo, 2015: 116-20.


2016

- Avbelj M, Zupanc D, Žagar T, Kotnik P, Jakil M, Pirnat E, et al. Rak ščitnice pri otrocih. In: Bešič N, Zaletel K, eds. Dan ščitnice. Ljubljana: Slovenska sekcija za onkološko kirurgijo SZD, 2016: 27.
- Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Primic Žakelj M, et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? *European journal of cancer*. 2016; 55: 47–55.
- de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Primic Žakelj M, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. *European journal of surgical oncology*. 2016; 42: 1414–9.
- Deandrea S, Molina-Barcelo A, Uluturk A, Primic Žakelj M, Jarm K, Krajc M, et al. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. *Preventive medicine*. 2016; 91: 250–63.
- Ivanuš U, Primic Žakelj M, Jerman T, Florjančič M, Kuster M, Takac I, et al. HPV self-sampling response rate in randomised study among Slovenian non-responders to the organised cervical cancer screening program. In: EUROGIN 2016 abstracts: part I - main conference program. Salzburg: EUROGIN, 2016: 333–4.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki: novi pristopi v primarni in sekundarni preventivi. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 106–7.
- Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Žagar T, et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. *European journal of cancer*. 2016; 67:183–90.
- Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Žagar T, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. *Hematological oncology*. 2016 Sep 19.
- Kokalj M, Zadnik V, Ančin A, Plavc G, Didanović V, Šifrer R, et al. Ploščatocelični karcinom neznanega izvora z zasevki v bezgavkah na vratu: vloga elektivnega obsevanja sluznice v področju glave in vratu = Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: the role of elective irradiation of mucosal sites. *Medicinski razgledi*. 2016; 55(S1): 297–301.
- Krajc M, Zadnik V. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 116–7.
- Mandelj N, Zadnik V. Breme želodčnega raka v Sloveniji z oceno pripisljivih deležev zaradi prekomernega vnosa soli ter prenizkega vnosa sadja in zelenjave. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 119–20.
- Primic Žakelj M. Prenovljen evropski kodeks proti raku = New edition of European code against cancer. *Gastroenterolog*. 2016; 20(S2): 5–11.
- Primic Žakelj M, Ivanuš U. Zgodnje odkrivanje raka materničnega vratu - program Zora = Screening for cervical cancer in Slovenia - programme Zora. *Gastroenterolog*. 2016; 20(S2): 72–7.
- Primic Žakelj M, Ivanuš U. Presejalni programi za raka. In: Novaković S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut; 2016. p. 14–23.
- Primic Žakelj M, Jarm K, Novak Mlakar D, Ivanuš U. Presejanje za raka: krhko ravnovesje med koristmi in škodo. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 110–1.
- Primic Žakelj M, Žagar T. Epidemiologija raka dojk. In: Borštnar S, Duratović Konjević A, Grašič-Kuhar C, eds. Zbornik prispevkov, Šola raka dojk. Ljubljana: Združenje za senologijo, SZD, 2016: 6–11.

- Strojani P, Kokalj M, Zadnik V, Anicin A, Plavc G, Didanovic V, et al. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation. *European archives of oto-rhino-laryngology* 2016; 273: 4561–9.
- Zadnik V. Onkološka epidemiologija čez desetletje. In: Novaković S, editor. *Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik*. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2016: 9-13.
- Zadnik V. Raziskovanje vpliva okolja na zbolevanje za rakom in ocenjevanje tveganja. In: Belovič B, Čemažar M, Perharič L, Primic Žakelj M, Zadnik V, Zdešar A, eds. *Kemikalije v okolju in rak*. Ljubljana: Zveza slovenskih društev za boj proti raku, 2016: 7–18.
- Zadnik V, Ivanuš U. Epidemiologija raka materničnega telesa. In: Merlo S, Smrkolj Š, Šegedin B, eds. *Rak materničnega telesa: zbornik*. Ljubljana: Združenje za radioterapijo in onkologijo SZD: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2016: 15–9.
- Zadnik V, Krajc M. Epidemiological trends of hormone-related cancers in Slovenia. *Arhiv za higijeno rada i toksikologiju*. 2016; 67: 83–92.
- Zadnik V, Žagar T, Jarm K, Primic Žakelj M. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2013. In: *Joining forces for better cancer registration in Europe*. Luxembourg: Publication Office of the European Union, 2016: 32.
- Zadnik V, Žagar T, Primic Žakelj M. Linkage to supplementary registration sources: key lessons learned in the last 30 years in Slovenia. In: Benider A, Zanetti R, Siesling S, Bray F, eds. *The 38th Annual IACR Conference*. Marrakech: IACR, 2016: 63.
- Zadnik V, Žagar T, Primic Žakelj M. Cancer Patients' Survival: Standard Calculation Methods And Some Considerations Regarding Their Interpretation. *Zdravstveno varstvo*. 2016; 55: 134–41.
- Žagar T, Zadnik V, Jarm K, Ivanuš U, Primic Žakelj M. Redki raki. In: Kraigher A, Berger T, Nikolič S, eds. *Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 115.







POROČILO RR št. 56
REPORT No. 56
Ljubljana 2017
ISSN 1318-5845